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To provide context for this thesis, the major research project was significantly impacted by the 
COVID-19 pandemic. A major research project to pilot an Acceptance and Commitment Therapy-
based group for patients with implantable cardioverter defibrillators had been developed between 
January 2019 and March 2020. However, major disruptions to NHS services occurring because of the 
COVID-19 pandemic led to the suspension of group therapies and routine cardiac services, with staff 
redeployed to other essential services. Due to this, the original planned project could not proceed. As 
a result, I developed and conducted a new project looking at psychological distress among people 
with heart failure during COVID-19 (see Appendix 2.6 for proposal). Due to continued COVID-related 
difficulties (such as research approval delays, charities and clinicians not being able to prioritise 
research recruitment due to other essential demands, and the long-term suspension of routine face-
to-face clinics), the sample size was smaller than planned. In line with guidance from the University 
of Glasgow, the analysis plan was revised to use appropriate statistical methods for the data 























Depression is common among people with heart failure (HF) and has been linked with adverse 
physical health outcomes. Previous research has identified several factors associated with depression 
in HF. This systematic review synthesises the published prospective longitudinal research examining 
predictors of depression in patients with HF.  
 
Methods 
Five databases (MEDLINE, EMBASE, CINAHL, PsycINFO and Cochrane Library) were systematically 
searched for relevant published literature from their inception until January 2021. Articles were 
assessed against eligibility criteria. Included studies were quality assessed using the National Heart, 
Lung and Blood Institute (NHLBI) quality assessment tool for observational cohort and cross-sectional 
studies. Narrative synthesis was used to summarise results. 
 
Results  
Thirteen studies were included. Demographic factors were investigated in eight studies, clinical 
factors in ten studies, psychological factors in six studies, and social and spiritual factors in ten 
studies. There was limited evidence that demographic or clinical factors predicted depression. There 
was evidence across multiple studies that negative health-related perceptions and lack of satisfaction 
with social support were independent predictors of subsequent depression.  
 
Conclusions 
Further prospective research is needed to clarify the role of predictors identified from single studies, 
and to increase understanding of mechanisms involved in the development of depression in people 
with HF. Focusing on modifiable risk factors, such as negative health-related perceptions and lack of 
satisfaction with social support, may have clinical utility in early identification of at-risk individuals 











Heart failure and depression 
Heart failure (HF) is a clinical syndrome in which structural and functional defects in cardiac muscle 
tissue result in the heart being unable to pump blood adequately around the body (Inamdar & 
Inamdar, 2016). HF is estimated to affect 1-2% of the United Kingdom (UK) population, with 
prevalence increasing with age (Sutherland, 2010). Average life expectancy is roughly three years 
following diagnosis (Royal College of Physicians, 2005). Treatment options for HF provide 
symptomatic relief but are not curative (Inamdar & Inamdar, 2016). Patients with HF often report a 
significant impact on functional status, reduced quality of life and poor general wellbeing 
(Sutherland, 2010).  
 
Depression is common among patients with HF (Faris et al., 2002; Maggioni et al., 2016; Westlake et 
al., 2005; Zahid et al., 2018), with prevalence rates for depression and anxiety disorders higher 
among people with HF than the general population (Celano et al., 2018). Previous meta-analyses 
estimate around 21.5% of patients with HF have clinically significant symptoms of depression 
(Rutledge et al., 2006). Depression has previously been associated with adverse health outcomes in 
patients with HF including increased risk of mortality at follow-up, greater morbidity, and increased 
use of healthcare resources (Celano et al., 2018; Cully et al., 2009; Rutledge et al., 2006; Sokoreli et 
al., 2016).  
 
Factors associated with depression in patients with heart failure 
Previous research suggests a number of demographic (e.g., age, gender), clinical (e.g., fatigue, 
severity of HF) and psychosocial factors (e.g., social support, coping style) are associated with 
psychological distress and depression among people with HF (Scherer et al., 2007; Trivedi et al., 
2009; Yu et al., 2004). However, much of this research has been cross-sectional. Cross-sectional 
studies are useful in identifying factors associated with depression but are not able to distinguish 
causal factors. Prospective, longitudinal studies are more informative in identifying potential causal 
factors which predict subsequent depression. To date, prospective longitudinal research into 
predictors of depression among people with HF has not been synthesised. The current review seeks 
to address this gap and provide a clearer account of factors associated with increased risk of 
depression in people with HF. This could be beneficial for psychological assessment among people 
with HF and identifying at-risk individuals for enhanced monitoring. Such factors may also indicate 






This systematic review aims to provide a synthesis and critical appraisal of the published prospective 
longitudinal research examining predictors of depression in patients with HF.  
 
Method 
Methodology for this systematic review followed the PRISMA statement for conducting and 
reporting systematic reviews (Page et al., 2021). The review protocol can be found at 
www.crd.org.uk/prospero (PROSPERO ID: CRD42021227023). 
 
Search strategy 
The following five databases were systematically searched for relevant studies: Medical Literature 
Analysis and Retrieval System Online (MEDLINE) and Excerpta Medica Database (EMBASE) via OVID; 
Cumulative Index to Nursing and Allied Health Literature (CINAHL) and PsycINFO via EBSCO, and 
Cochrane Library. Three main concepts of HF, depression and prospective study design were mapped 
to the most relevant controlled vocabulary using Medical Subject Headings (MeSH) with free-text 
items added where necessary. The SIGN Observational Studies search filter (Scottish Intercollegiate 
Guidelines Network, 2020) was adapted for the prospective study design concept. Full search 
strategies for each database are provided in Appendix 1.2. Databases were searched between their 
inception date and date of search (22nd January 2021). Backward and forward citation searches of 
references of included articles were completed to check for any additional relevant studies. 
 
Eligibility criteria 
Articles were eligible for review if: 1) research design was prospective/longitudinal; 2) subjects were 
adult patients who had been diagnosed with HF; 3) data were reported concerning baseline 
predictors of subsequent depression; and 4) depression was measured using validated outcome 
measures. Studies looking at mixed cardiac populations (i.e., those where only some participants had 
HF) and those using data gathered as part of a clinical intervention trial which may have influenced 
symptoms of depression were excluded. Studies were also excluded if they: 1) utilised a qualitative 
or mixed methods design; 2) were not published in a peer-reviewed journal (i.e., editorials, 
dissertations, conference articles); or 3) were not written in English. 
 
Data selection process 
Following de-duplication, titles and abstracts of identified studies were screened by the primary 
reviewer against the inclusion/exclusion criteria. The full texts of potentially relevant articles were 
then retrieved and assessed against the same eligibility criteria by the primary reviewer.  
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Data extraction  
Data extracted included general study information (author(s), date of publication, country), 
recruitment and follow-up procedures, key inclusion and exclusion criteria, participant numbers (at 
baseline and follow-up) and characteristics (gender, age, HF characteristics), depression measure(s) 
used, predictors investigated, prevalence of depression, data pertaining to the relationship between 
predictor variables and depression, confounders controlled for and any additional relevant analysis. 
 
Quality assessment 
The quality of included articles was assessed using the National Heart, Lung, and Blood Institute 
(NHLBI) quality assessment tool for observational cohort and cross-sectional studies (National 
Institutes of Health, n.d.). The NHLBI tools are study-design specific, widely used and were developed 
by researchers collaborating from organisations such as the Cochrane Collaboration, SIGN, and 
National Health Service Centre for Reviews and Dissemination (Jorgensen, 2015; National Heart Lung 
and Blood Institute, n.d.). The observational cohort and cross-sectional studies tool comprises 14 
items to assess study quality and risk of bias (see Appendix 1.3). Items were marked ‘yes’, ‘no’, or 
‘other’.  Items scored ‘other’ were coded as either ‘cannot determine’, ‘not applicable’ or ‘not 
reported’. Individual item scores were used to guide an overall quality rating of ‘good’, ‘fair’ or ‘poor’. 
Two researchers independently rated all included articles using the NHLBI quality assessment tool.  
 
Data analysis and synthesis 
Due to heterogeneity across included studies, data were summarised narratively using 
recommended guidelines for narrative synthesis (Popay et al., 2006). Based on previous studies 
looking at predictors of depression (Cook et al., 2018; Fisher et al., 2019; Tibubos et al., 2019) and 
the predictors identified in included studies, results were synthesised and grouped into four broad 
categories: demographic, clinical, psychological, and social and spiritual predictors. Clinical factors 
included both factors related to HF and more general physical health factors. 
 
Results  
The search identified 5,767 unique records. Of these, 5,700 were excluded based on title and 
abstract screening. Full-text articles of the remaining 67 records were accessed with 55 excluded 
following application of the eligibility criteria resulting in 12 included articles. One additional article 
was identified from backward and forward citation searches of included articles. Therefore, 13 
articles were included and are reported in this systematic review. Figure 1 outlines the search results 




































Figure 1: PRISMA study selection flowchart. 
 
Study characteristics 
Table 1 describes the characteristics of the 13 included studies. Studies were published between 
2004 and 2020. Most studies (n = 8; 61.5%) were conducted in the United States, with one study 
conducted in both the United States and Canada. The remaining four studies were conducted in 
Germany (n = 2), the Netherlands (n = 1), and Japan (n = 1). Mean sample ages ranged from 58.9 to 
69.5 years and the average proportion of males was 70.2%. Race was reported in eight studies and 
participants were mostly Caucasian (75.9%). Eleven studies recruited outpatients, one study 
recruited patients at discharge, and one study did not explicitly describe their study population. 
Study participants varied in terms of HF illness severity, as measured by the 4-point New York Heart 
Association (NYHA) classification system where higher classification indicates greater symptom 
severity and functional limitations. Six studies had predominately NYHA class I or II participants, two 
Records identified from 
databases (n = 9,048): 
MEDLINE (n = 2,182) 
Embase (n = 4,449)  
CINAHL (n = 974) 
PsycINFO (n = 930) 
Cochrane Library (n = 513) 
Records removed before 
screening: 
Duplicate records 
removed (n = 3,281) 
 
Records screened (n = 5,767) 
Records excluded  
(n = 5,700) 
Reports assessed for 
eligibility (n = 67) 
Additional records 
identified from citation 
searching (n = 1) 
Reports excluded (n = 55): 
Not prospective design  
(n = 24)  
Not looking at baseline 
predictors of 
subsequent depression 
(n = 16) 
Not peer-reviewed 
publication (n = 7) 
Population not HF-
specific (n = 4) 
Part of trial (n = 4) 
Studies included in review and 






























studies had predominately NYHA class III or IV participants, and two studies only included 
participants with NYHA class III or IV. Two studies did not report NYHA class. Eight studies reported 
prevalence of clinically significant depression scores: mean prevalence of scores above the clinical cut 
off was 19.9% (range 12.9-38.6%).  
 
Most of the included studies (n = 12) relied on the following self-report scales to measure the 
depression outcome: Center for Epidemiological Studies – Depression (CES-D) (n = 5); Patient Health 
Questionnaire-9 (PHQ-9) German version (n = 2); Medical Outcomes Study-Depression (MOS-D) (n = 
1); Beck Depression Inventory (BDI) (n = 1); BDI-II (n = 1); Hospital Anxiety and Depression Scale-
Depression subscale (HADS-D) (n = 1); and HADS-D Dutch version (n = 1). One study used both a 
structured clinical interview tool (Structured Clinical Interview for DSM-IV; SCID) and self-report scale 
(Geriatric Depression Scale; GDS) to measure depression (Turvey et al., 2006). Three studies only 
recruited participants without depression at baseline, nine studies controlled for baseline depression 
in statistical analysis and one study did not report whether baseline depression had been controlled 
for.  
 
Self-report measures were primarily used to assess clinical, demographic, psychological, social and 
spiritual predictors. Clinical predictors were also assessed through medical record review and/or use 
of objective physical measurements, such as resting blood pressure, blood sampling and transcranial 
doppler ultrasonography. Most studies analysed data using either linear (n = 8) or logistic (n = 3) 
regression while two studies used structural equation modelling. There was substantial variation in 
method of analysis and order of entry of predictors into models. 
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Methodological quality 
Results from the quality assessment are presented in Table 2. Inter-rater reliability was 86.3% (κ = 
.65, 95% CI, 0.531-0.774). Discrepancies in scoring between raters mainly arose in relation to 
whether reporting of recruitment time period was necessary in defining the study population, 
whether exposure(s) had been assessed more than once over time, and how studies had reported 
participation and loss to follow-up rates. Discrepancies in scoring were resolved through discussion 
and are reported in Appendices 1.4 and 1.5.  
 
Quality of included studies varied but was generally good. All studies measured the exposure(s) of 
interest prior to the depression outcome and had a sufficient follow-up timeframe (minimum 3 
months). Exposure and outcome measures were generally well-defined and examined using 
appropriate methods. Seven studies did not report the percentage of eligible individuals who took 
part, and one study had a low participation rate (49%). Eleven studies did not provide sample size 
justifications and one study acknowledged it may have been underpowered. The lack of power 
calculations may be explained by the exploratory nature of analyses for most included studies. Only 
five studies reported loss to follow-up of 20% or less: four studies lost more than 20% of participants 
to follow-up and four did not report loss to follow-up. One study did not control for baseline 
depression in analysis and one study included follow-up variables in statistical modelling, so it was 
unclear which baseline factors were independent predictors of subsequent depression. Overall 




A summary of predictors tested and study findings are presented in Table 2. From the included 
studies, there was limited evidence that demographic variables predicted depression among people 
with HF. Age was assessed as a predictor of depression in six studies, with two finding a significant 
effect. Younger age predicted higher depression score 6 months later (Carney et al., 2020) and was 
an independent predictor of clinically elevated depression levels at 12-month follow-up (Brouwers et 
al., 2014). However, four studies found age was not a significant predictor of depression at 6- or 12-
month follow-up (Alosco et al., 2014; Lossnitzer et al., 2013; Park et al., 2006; Park & Lee, 2020). All 
six studies had similar samples in terms of mean age and four studies were of good quality (two 
significant, two non-significant) so the reason for disparities in findings is unclear. However, the odds 
ratio confidence interval for age in the Brouwers et al. (2014) study was close to non-significance 
(0.85-0.99) and Lossnitzer et al.’s (2013) non-significant finding was from a particularly large sample 
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size of participants free from depression at baseline. Thus, further investigation is warranted as there 
is not consistent evidence that younger age is a predictor of depression among people with HF.  
 
Perception of medical care as being a substantial economic burden was also found to be a significant 
predictor of clinically relevant depressive symptoms at 12-month follow-up (Havranek et al., 2004). 
However, this study was based in the United States and Canada where healthcare costs may be more 
likely to result in socioeconomic hardship than countries such as Japan or the UK which have 
universal healthcare systems. This finding may therefore be specific to North America or to countries 
with greater healthcare costs for the individual.  
 
No other demographic variables were significant predictors of subsequent depression in the included 
studies; gender (Alosco et al., 2014; Brouwers et al., 2014; Carney et al., 2020; Lossnitzer et al., 2013; 
Park & Lee, 2020; Shimizu et al., 2014), race (Carney et al., 2020; Park et al., 2006; Park & Lee, 2020), 
educational level (Brouwers et al., 2014; Lossnitzer et al., 2013), marital status (Brouwers et al., 2014; 
Park & Lee, 2020) and health insurance status (Havranek et al., 2004) were all found to be non-
significant. Given that non-significant findings for gender were consistently indicated by multiple 
studies with low risk of bias, gender does not appear to be a significant independent predictor of 
depression. However, females were underrepresented in all studies which may have skewed results. 
Further research using representative samples is therefore warranted to clarify whether any 
demographic variables are independent predictors of depression among people with HF.  
 
Clinical predictors 
Clinical predictors were examined in ten of the thirteen included studies, with mixed findings. Five 
studies evaluated NYHA class (Alosco et al., 2014; Brouwers et al., 2014; Lossnitzer et al., 2020; 
Lossnitzer et al., 2013; Park et al., 2006), but only Lossnitzer et al. (2013) found NYHA class to be a 
significant predictor of incident depression at 12-month follow-up. The reason for this variation may 
be due to differences in the study population as Lossnitzer et al. (2013) only recruited participants 
free of depression at baseline whereas the other studies used non-selected HF cohorts. One study 
found reduced cerebral blood flow-velocity (CBF-V) predicted greater depressive symptomatology at 
12-month follow-up (Alosco et al., 2014). Other disease severity factors were assessed as possible 
predictors in five studies, but all were found to be non-significant: left ventricular ejection fraction 
(LVEF) (Brouwers et al., 2014; Carney et al., 2020; Lossnitzer et al., 2020; Lossnitzer et al., 2013; Park 
& Lee, 2020), ischemic aetiology (Brouwers et al., 2014; Lossnitzer et al., 2013), brain natriuretic 
peptide (BNP) (Brouwers et al., 2014), and N-terminal-prohormone B-type natriuretic peptide (NT-
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proBNP) (Lossnitzer et al., 2020). Similarly, blood measures, such as haemoglobin, estimated 
glomerular filtration rate and hyponatremia, did not predict depression (Lossnitzer et al., 2013). 
 
Two studies investigated inflammation markers as possible predictors of depression (Brouwers et al., 
2014; Wirtz et al., 2010). Soluble intercellular adhesion molecule (sICAM-1) was found to predict 7-
10% of the total variance in depression scores after controlling for confounders at 12-month follow-
up in a small sample of 30 HF patients (Wirtz et al., 2010). No other inflammation variables tested 
(TNFsr1, TNFsr2, TNFα, IL-6, IL-10, CRP) were found to predict depression (Brouwers et al., 2014; 
Wirtz et al., 2010). Wirtz et al.’s (2010) study was of lower quality than Brouwers et al.’s (2014) which 
did not include sICAM-1. Therefore, further investigation is needed to confirm whether sICAM-1 is a 
true predictor of depression.  
 
There was limited evidence that comorbidities predicted subsequent depression. The total number 
of comorbidities did not predict depressive symptoms at 6-month follow-up (Park & Lee, 2020). 
However, higher comorbidity index score was an independent predictor of clinically elevated 
depression levels at 12-months (Brouwers et al., 2014). Compared to Park and Lee (2020), the 
Brouwers et al. (2014) study was of higher quality, had a longer follow-up period, and used an index 
score which adjusted for comorbidity weights and age. This suggests comorbidity index score 
warrants further investigation as a possible predictor of subsequent depression.  
 
Previous diagnosis of ischemic heart disease (Shimizu et al., 2014), history of resuscitation (Lossnitzer 
et al., 2013) and frequent GP visits (Lossnitzer et al., 2013) were all found to predict incidence of 
significant depressive symptoms 12-months later. However, diabetes (Alosco et al., 2014; Havranek 
et al., 2004; Lossnitzer et al., 2013; Shimizu et al., 2014), hypertension (Alosco et al., 2014; Havranek 
et al., 2004; Lossnitzer et al., 2013; Shimizu et al., 2014), sleep apnoea (Alosco et al., 2014), body 
mass index (BMI) (Brouwers et al., 2014), 6-minute walk test (Shimizu et al., 2014), and knee muscle 
strength (Shimizu et al., 2014) did not predict subsequent depression scores. Medication predictors 
were generally found to be non-significant (Brouwers et al., 2014; Lossnitzer et al., 2013). However, 
further investigation is warranted regarding statin use which Brouwers et al. (2014) found predicted 
depressive symptoms at 12-months follow-up. 
 
Two studies investigated lifestyle predictors. Alcohol consumption was non-significant (Lossnitzer et 
al., 2013) but alcohol abuse was a significant predictor of clinically relevant depressive symptoms at 
12-month follow-up (Havranek et al., 2004). Smoking was found to predict incidence of depression 
12-months later (Lossnitzer et al., 2013). Both studies were of good quality, but further research is 
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needed to validate these individual findings and to investigate the cut-off at which alcohol use may 
become a significant predictor. 
 
Psychological predictors 
Psychological predictors were evaluated in six studies. There was evidence that health-related 
perceptions predicted depression. Lower perceived health status was found to predict clinically 
relevant depressive symptoms at 12-month follow-up (Havranek et al., 2004). Similarly, appraisals of 
one’s illness as threatening (Park et al., 2006) and negative attitudes about impairment (Turvey et al., 
2006) were found to predict higher levels of depression at 6-month follow-up. However, both these 
studies were of fair quality so further investigation is warranted to validate these findings. Two 
studies reported on subjective physical impairment with inconsistent findings between the studies. 
Perceived physical impairment was not a significant predictor of depression score at 6-month follow-
up (Turvey et al., 2006) but was an independent predictor of incident depression at 12-month follow-
up (Lossnitzer et al., 2013). Compared to Turvey et al.’s (2006) study, Lossnitzer et al. (2013) had a 
much larger sample size and lower risk of bias so the differences between studies may be due to 
methodological quality and power rather than length of follow-up. Shimizu et al. (2014) found 
participation restrictions (i.e., the extent to which individuals feel limited in interpersonal 
interactions and activities in community life) predicted clinically relevant depressive symptoms at 12-
month follow-up, but functional limitations did not. This fits with the other studies suggesting that 
patient’s perceptions of their health may be more closely related to depression than physical health 
variables. 
 
Other psychological predictors were assessed in three studies. In Lossnitzer et al.’s (2013) study, 
which only included participants without baseline depression, both previous history of depression 
and baseline depression score were found to predict incident depression at 12-month follow-up. 
Type D personality was found to predict depression symptoms at 12-month follow-up (Brouwers et 
al., 2014). Active coping predicted lower levels of depression at 6-month follow-up, but appraisals of 
HF as challenging did not prospectively predict depression (Park et al., 2006). 
 
Social and spiritual predictors 
Seven studies investigated predictors related to social support, with mixed findings. Havranek et al. 
(2004) found living alone to be an independent predictor of developing clinically relevant depressive 
symptoms at 12-month follow-up. However, Lossnitzer et al. (2013) found that whilst living alone 
was significantly correlated with incident depression in univariate analysis, it lost significance when 
included in the final regression model. Both studies were of good quality, only included HF patients 
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without depression at baseline and had similar samples in terms of age, gender and NYHA class. 
Differences between studies may therefore be due to the specific predictors included in statistical 
models or the lower proportion of participants living alone in the Lossnitzer et al. (2013) study 
compared to Havranek et al. (2004) (16.8% compared to 26.5%). Satisfaction with social support was 
assessed in two studies, with lack of satisfaction with social support found to predict depression 
scores at 6-month follow-up (Park et al., 2006) and clinically relevant depressive symptoms at 12-
month follow-up (Shimizu et al., 2014). However, perceived social support was not a significant 
predictor (Turvey et al., 2006). This study had a low response rate and small sample size (N=32) so 
limited statistical power may have led to a type II error. Level of social support (Park & Lee, 2020), 
number of social supports (Park et al., 2006; Shimizu et al., 2014), and loneliness (Brouwers et al., 
2014) also did not predict subsequent depression.  
 
Religion and spirituality variables were assessed in four studies, but there was limited evidence that 
these variables predicted depression. Two studies found significant results, and these were mixed. 
Park and Lee (2020) found spiritual peace to be a significant predictor of lower levels of depression, 
whereas Carney et al. (2020) found increases in belief in God predicted higher depression scores at 6-
month follow-up. However, neither of these studies reported their participation rates and Park and 
Lee (2020) did not report loss to follow-up, making it difficult to determine how representative the 
samples were. All other religious and spirituality variables investigated were found to be non-
significant: e.g., service attendance, belief in afterlife, religious struggle, religious identity (Carney et 
al., 2020; Park & Lee, 2020; Park et al., 2014; Park et al., 2011). 
 
The impact of increasing number of independent predictors 
Three studies reported on risk of incident depression with increasing number of identified risk factors 
(i.e., those variables found to be independent predictors of subsequent depression risk) (Havranek et 
al., 2004; Lossnitzer et al., 2013; Shimizu et al., 2014). Havranek et al. (2004) and Shimizu et al. (2014) 
had comparable findings with incidence of depression at 0% or 8% with zero risk factors and 71% or 
69% with three risk factors, respectively. Similarly, Lossnitzer et al. (2013) reported incidence rates of 
16% for minor depression and 23% for major depression when more than three risk factors were 
present. Thus, whilst the risk factors identified differed between studies, all three studies found 
cumulative effects, such that incidence of depression increased with increasing number of 







This systematic review examined predictors of depression in people with HF. Identifying predictors of 
depression is of clinical relevance among people with HF given the increased prevalence of 
depression (Celano et al., 2018; Rutledge et al., 2006) and previously established links with adverse 
health outcomes (Celano et al., 2018; Cully et al., 2009; Rutledge et al., 2006; Sokoreli et al., 2016). 
There was little consistent evidence that any demographic or clinical variables reliably predicted 
depression. Significant predictors were found only in single studies or findings were inconsistent 
between studies, highlighting the need for further research. Further investigation of these factors 
(e.g., younger age, comorbidity index score, alcohol use) is needed to clarify their predictive roles. 
 
There was, however, evidence that several psychological factors predict depression among people 
with HF. Cognitive appraisals associated with health status (e.g., perceptions of one’s illness as 
threatening and negative attitudes about impairment) were found to predict depression in three 
studies (Havranek et al., 2004; Park et al., 2006; Turvey et al., 2006). This is consistent with 
Leventhal’s Common-Sense Model of illness which posits that individuals develop cognitive and 
emotional representations of illness threat which directly influence coping responses and thus 
subsequent outcomes (Leventhal et al., 2003). Negative appraisals of health status may also 
contribute to ongoing depressive symptomatology with both factors influencing each other in a 
downwards spiral (Park et al., 2006; Turvey et al., 2006). These negative appraisals are modifiable 
factors which could potentially be targeted directly in interventions, e.g., through cognitive 
behavioural therapy (CBT). Previous CBT trials for patients with HF have shown efficacy in reducing 
depressive symptoms (see review by Celano et al. (2018)). Further research should ascertain the 
underlying mechanisms and determine whether improvements are due to changes in cognitive 
appraisals. Screening for negative health-related perceptions may highlight individuals at risk of 
developing depression who could be targeted by psychological interventions such as CBT. 
 
There was also evidence that lack of satisfaction with social support predicted depression (Park et al., 
2006; Shimizu et al., 2014). The construct of social support is multidimensional (Cohen et al., 1985), 
and findings for other social support variables were generally non-significant. This is consistent with a 
previous 10-year population-based cohort study by Teo et al. (2013) which found poor quality of 
social relationships predicted depression, but social isolation did not. Previous research among 
people with HF has found decreased belonging support to be related to increased likelihood of 
depression (Graven et al., 2017). Similarly, Heo et al. (2014) found emotional support (i.e., 
individuals’ perceptions of affective support from family, friends and important others) was related 
to depressive symptoms in people with HF whereas other types of social support were not. Thus, 
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perceptions of social support appear to be more closely linked with the development of depression. 
Focusing on satisfaction with social support and improving how connected people feel with those 
around them may reduce the likelihood of future depressive symptomatology. 
 
There was also good evidence that higher levels of cumulative risk were associated with increased 
incidence of depression. This suggests the development of depression is multifaceted, and that both 
individual risk factors and the total number of these should be considered when developing 
screening methods and understanding depression risk. 
 
Strengths and limitations 
A strength of the review is that it focused solely on prospective, longitudinal studies. Such studies are 
more informative in identifying potential causal mechanisms for the development of depressive 
symptoms in people with HF. Overall quality of included studies was generally good, and most 
studies controlled for baseline depression either in study design or analysis methods. There was good 
evidence for two predictors – negative health-related perceptions and lack of satisfaction with social 
support – and for a cumulative impact of increasing number of independent predictors on depression 
risk.  
 
Publication and outcome reporting biases may have resulted in significant findings being more likely 
to be reported than non-significant results. Included studies were heterogenous and varied in terms 
of inclusion criteria, length of follow-up and types of depression measures used, making comparisons 
between studies and interpretation of findings difficult. For instance, there could be differences in 
significant predictors depending on length of follow-up period. Such nuances warrant further 
investigation. A previous large representative UK cohort study of newly diagnosed HF patients found 
mean age of 76.6 and proportion of males to be 51% (Conrad et al., 2019). The sample from included 
studies in this review was therefore younger and predominantly more male than the wider UK HF 
population. Most studies were exploratory and sample sizes may not have been large enough to be 
sufficiently powered. In addition, sampling and attrition biases across studies may be an issue as 
most studies did not report participation and follow-up rates. Findings from studies with smaller 
sample sizes warrant future follow-up with appropriately sized representative samples.  
 
Most studies (with one exception) used self-reported measures of depression, and eight studies did 
not report caseness cut-offs. Self-report measures have previously been found to have weak 
agreement with clinical interviews for diagnosis of depression (Eaton et al., 2000). This limits validity 
of prevalence estimates for depression as variation in depression assessment methods and caseness 
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cut-offs have previously been found to have the biggest impact on reported depression rates in 
studies of people with HF (Rutledge et al., 2006). In addition, most studies operationalised the 
dependant variable as depressive symptoms measured on a continuous scale, rather than applying 
caseness cut-offs for analysis. Predictors of depression score should not be misinterpreted as 
predictors of depressive disorder.  
 
Implications for future research  
Given the significant impact of depression for people with HF, it is apparent more high-quality 
prospective studies are needed. Further investigation of inconsistencies across studies and predictors 
identified in single studies is warranted to determine whether these represent true risk factors for 
the development of depression in people with HF. Adequately powered studies with large sample 
sizes, more representative samples, and tracking participants at multiple time points for longer 
follow-up periods are needed to move beyond exploratory findings. This has clinical utility for early 
identification of at-risk individuals with HF and identifying key modifiable factors which could be 
targeted by early intervention. HF has become an increasingly heterogenous clinical syndrome with 
several distinct subtypes and ever-increasing clinical complexity (due to aging populations and 
advances in cardiovascular treatment) (Iorio et al., 2017). It may be helpful to explore whether 
predictors of depression differ between subtype groups, or are impacted by related factors, such as 
time since diagnosis, treatment pathways, and rate of progression of illness. Future studies may also 
benefit from carefully rationalising caseness cut-offs and use of clinical interview methods. 
 
Identified psychological and social predictors of depression, particularly negative health-related 
perceptions and lack of satisfaction with social support, highlight potentially modifiable factors which 
could be targeted by early intervention. It would be beneficial to explore key factors which may 
influence health-related perceptions and therefore represent areas for intervention, such as 
information given at time of diagnosis, attitudes of caregivers, communication with health 
professionals and coping responses. Further research is needed to test whether screening for 
psychological/social predictors and targeting at-risk individuals with early intervention leads to 
reduced depressive symptomatology. 
 
Conclusion 
This review is the first to systematically identify and synthesise the prospective research evidence 
investigating predictors of depression in people with HF. The thirteen included studies identified 
several significant predictors, but these were often detected in single studies and there were 
inconsistencies across studies. This review found no consistent evidence that any demographic or 
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clinical variables reliably predicted depression. However, two psychological/social factors were 
consistent predictors: negative health-related perceptions and lack of satisfaction with social 
support. Focusing on these potentially modifiable risk factors may allow at-risk individuals to be 
identified early and supported with targeted interventions. Further prospective research is needed to 
increase understanding of predictors of depression among people with HF as focus in these areas has 
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Plain Language Summary 
Title 
An exploration of mental health and variables associated with psychological distress among people 
with heart failure during the COVID-19 pandemic. 
 
Background 
In this study, psychological distress is defined as significant symptoms of depression and/or anxiety. 
In the United Kingdom, rates of psychological distress increased during the COVID-19 pandemic 
(Shevlin et al., 2020). Before COVID-19, people with heart failure (HF) had higher rates of 
psychological distress than the general population (Celano et al., 2018). People with HF are at greater 
risk of becoming unwell and dying from COVID-19. Thus, people with HF might be at greater risk of 
psychological distress during COVID-19. We looked at rates of psychological distress among people 
with HF compared to a control group. Psychological distress has also been linked with other factors. 
For instance, age, gender, having other health conditions, fatigue, and social support. These factors 
may be linked to psychological distress for HF patients during COVID-19. 
 
Aims 
The main aim was to examine rates of psychological distress during COVID-19 among people with HF 




Fifty-seven participants (42 with HF and 15 controls) took part in the study. Recruitment was through 
heart failure organisations and charities across Scotland. These groups shared the study 
advertisement through social media networks, support groups and routine clinical contact. For the 
control group, HF participants were asked to pass the study information to 2-3 close friends (known 
as snowball sampling). To take part, participants filled in an online questionnaire that took 10-15 
minutes to complete.  
 
Main findings and conclusions 
There were no significant differences in psychological distress in the HF group compared to controls. 
Overall, 33.9% of participants had significant symptoms of depression and 19.6% had anxiety 
symptoms. We found higher depression rates and lower anxiety rates than other HF and COVID-19 
studies. The snowball sampling method was not able to recruit a control sample that was similarly 
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sized to the HF group. In the HF group, psychological distress was related to several other variables 
such as perceived control, loneliness, and having other health conditions. Further research into these 
factors would be useful for psychological assessment and intervention. 
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People with heart failure (HF) have increased vulnerability to COVID-19 and may be at increased risk 
of psychological distress. The primary aim of this study was to describe rates of psychological distress 
among people with HF compared to controls during the COVID-19 pandemic. The study also aimed to 
investigate other variables potentially associated with psychological distress.  
 
Design 
A case-control, cross-sectional design was developed to investigate rates of psychological distress 
and related variables among people with HF during the COVID-19 pandemic. A feasibility approach 
was taken to explore use of a snowball sampling method with HF participants to recruit a 
demographically matched control sample. 
 
Methods 
Fifty-seven participants (42 with HF and 15 controls) completed an online questionnaire consisting of 




Depression prevalence was 33.9% and anxiety prevalence was 19.6%. There were no significant 
differences in rates of psychological distress in the HF group compared to controls. For the HF group, 
medium-large effect sizes were found between depressive and anxiety symptoms and several related 
variables, such as perceived control, loneliness, and presence of other health conditions. 
  
Conclusions 
This study extended previous COVID-19 research to a HF population. The study found higher 
depression rates and lower anxiety rates than previously reported by other HF and COVID-19 studies. 
Related factors associated with psychological distress warrant further investigation as they may be 
useful in identifying at-risk individuals and potentially modifiable targets for intervention.  
 








Background context: COVID-19 and heart failure 
In response to the COVID-19 pandemic, the United Kingdom (UK) government imposed social 
distancing measures to reduce transmission, protect vulnerable individuals and manage health 
service demands (Cabinet Office, 2020; McBride et al., 2021). Tiered approaches and ‘lockdowns’ 
have been imposed following surges in cases and new virus strains (Public Health England, 2020a; 
Scottish Government, 2021a, 2021b). People with heart failure (HF) are at increased risk of 
hospitalisation, poor outcomes, and death from COVID-19 (Bader et al., 2021; Yonas et al., 2020). 
National guidance emphasised minimising the risk of contracting COVID-19 (Scottish Government, 
2020) and high-risk individuals with HF were advised to ‘shield’ by staying at home and avoiding face-
to-face contact (Public Health England, 2020b). 
 
Psychological distress and COVID-19 
In line with previous research, psychological distress will be defined as a “state of emotional suffering 
characterized by symptoms of depression and anxiety” (Drapeau et al., 2012, p. 105). There was 
increased prevalence of clinically significant levels of psychological distress among the UK population 
during the first lockdown compared to pre-COVID-19 levels (Kwong et al., 2020; Pierce et al., 2020; 
Shevlin et al., 2020). For instance, Daly et al. (2020) found population prevalence of mental health 
problems increased from 24.3% in 2017-2019 to 37.8% in April 2020 and remained elevated in May 
and June 2020 (34.7% and 31.9% respectively). Population-level evidence from previous infectious 
respiratory disease outbreaks suggests psychological distress may persist, or even worsen, over time 
(Gardner & Moallef, 2015; McBride et al., 2021). Bonanno et al. (2008) studied patients with severe 
acute respiratory syndrome in Hong Kong and found 42% of survivors reported poorer psychological 
functioning that persisted over time and 13% experienced delayed reactions with initially high 
psychological functioning which subsequently steeply declined. Thus, some individuals may 
experience more chronic stress responses during the COVID-19 pandemic and persistent difficulties 
with depressive and/or anxiety symptoms. Large numbers of population-level, cross-sectional, self-
report research studies have provided valuable insights into population-level psychological distress 
and coping during COVID-19. However, this approach may be less useful for understanding needs of 
specific subgroups, such as people with HF. 
 
Leventhal’s Common-Sense Model of illness posits that when threats are perceived, individuals 
develop cognitive and emotional representations of these which directly influence coping responses 
and outcomes (Leventhal et al., 2003). Based on this model, factors such as illness severity, perceived 
control, and coping style will influence psychological adjustment to health threats, such as COVID-19. 
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Previous research looking at psychological outcomes following traumatic events, including disease 
outbreaks, suggests psychological adjustment is influenced by other factors – such as age, gender, 
education, physical health, trauma exposure, disease fears, social support and coping style (Bonanno 
et al., 2007; Polizzi et al., 2020; Xu et al., 2011). Gaining better understanding of factors associated 
with psychological distress and adjustment during COVID-19 may help to inform psychological 
assessment, build understanding of maintenance and/or remission of psychological distress, and 
guide interventions to improve mental wellbeing (Holmes et al., 2020).  
 
Heart failure and psychological distress 
Prior to COVID-19, prevalence rates for depression and anxiety disorders were higher among people 
with HF than the general population (Celano et al., 2018). Previous meta-analysis estimated around 
21.5% of HF patients had clinically significant depressive symptoms (Rutledge et al., 2006), compared 
to an estimated UK population prevalence of 7.4% (Arias-de la Torre et al., 2021). Similarly, around 
28.8% of HF patients had clinically significant anxiety (Easton et al., 2016), compared to an estimated 
7.2% of adults in UK primary care (Martín-Merino et al., 2010). Emerging evidence suggests 
individuals classed as vulnerable during COVID-19 due to pre-existing health conditions may have 
experienced higher levels of psychological distress (Pierce et al., 2020; Shevlin et al., 2020), 
particularly anxiety (Rettie & Daniels, 2020; Westcott et al., 2021), than the general population. This 
may be due to additional stressors such as increased health- and finance-related anxieties, social 
isolation and disrupted access to health and social care services (Brooks et al., 2020; Holmes et al., 
2020; Scottish Government, 2020). However, studies have tended to include presence of pre-existing 
health conditions generally within population-level research rather than focusing specifically on 
these ‘vulnerable’ groups. Given HF patients have previously been found to have higher rates of 
psychological distress than the general population, they may represent a particularly at-risk group 
during the COVID-19 pandemic.  
 
Psychological distress among HF patients has previously been associated with sociodemographic 
characteristics (such as age, sex and employment status) (Holly & Sharp, 2012; Scherer et al., 2007), 
number of health problems (Holly & Sharp, 2012; Scherer et al., 2007), greater HF severity (Scherer 
et al., 2007), fatigue (Yu et al., 2004), avoidant coping and pessimism (Trivedi et al., 2009). 
Conversely, living with a partner and high levels of social support appear to be protective for HF 
patients, and increase the likelihood and speed of psychological distress reducing over time (Koenig, 
1998; Scherer et al., 2007; Trivedi et al., 2009; Yu et al., 2004). Thus, previous findings in relation to 
psychological adjustment to disease outbreaks and among HF patients suggest other 
sociodemographic, health and psychosocial factors may be significantly related to psychological 
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distress for people with HF during the COVID-19 pandemic. Given that psychological distress can 
persist or even worsen over time, identifying key related factors may be important as healthcare 
services move from COVID-19 crisis management into recovery phases. 
 
Aims 
The primary aim of this study was to describe rates of psychological distress among people with HF 
compared to controls during the COVID-19 pandemic. The study also aimed to investigate variables 
potentially associated with psychological distress.  
 
Hypotheses 
Based on previous literature, it was predicted that:  
1. Psychological distress would be higher among people with HF compared to controls.  
2. Psychological distress would be associated with other variables among people with HF, such 
as socio-demographic (age, gender, marital status), health (HF severity, shielding status, 
presence of other health conditions, fatigue) and psychosocial factors (coping style, 




A case-control, cross-sectional design was employed to investigate rates of psychological distress and 
related variables among HF patients and controls during the COVID-19 pandemic. A feasibility 
approach was taken to explore using a snowball sampling method with HF participants to recruit a 
demographically matched control sample. 
 
Participants and recruitment procedure 
A total of 57 participants took part: 42 HF and 15 control participants. Participants were eligible if 
they were aged 18 years or over, able to understand English, and resident in Scotland. Participants 
also needed the technology and ability to complete the questionnaire online.  
 
HF participants were recruited through the Heart Failure Hub Scotland (HFHS), Scottish Heart Failure 
Nurse Forum (SHFNF) and three national charities: Cardiomyopathy UK, Chest Heart Stroke Scotland, 
and British Heart Foundation. These organisations shared the study advertisement through their 
social media networks and support groups. Through the HFHS and SHFNF, HF clinicians across 
approved Scottish health boards were also informed of the study and invited to share the study 




A snowball sampling method (Goodman, 1961) was used to recruit control participants. Snowball 
sampling can increase likelihood of recruiting demographically matched samples and has been used 
in health research for case-control designs (Lopes et al., 1996; Rezaei et al., 2011). HF participants 
were asked to invite 2-3 close friends not living within the same household to participate as controls.  
 
Ethics 
Ethical approval was granted by NHS Greater Glasgow and Clyde (NHSGG&C) West of Scotland 
Research Ethics Service (WoSRES; Reference: 20/WS/0136) on 26th October 2020 with an 
amendment to include Golden Jubilee National Hospital granted on 17th December 2020 (Appendix 
2.1). NHSGG&C Research and Innovation (R&I; Reference: GN20CA363) agreed to host the research 
project with approval granted on 11th December 2020 (Appendix 2.2). R&D agreements for the HFHS 
and SHFNF to share the study with HF clinicians in 11 Scottish health boards were granted between 
11th December 2020 and 27th April 2021 (Appendix 2.3). 
 
Procedures 
Data were collected between 17th December 2020 and 14th May 2021. Potential participants 
accessed the webpage provided on the study advertisement (Appendix 2.4). They were provided 
with an online Participant Information Sheet (Appendix 2.5) and completed short screening 
questions to ensure eligibility. As responses were anonymised, submission of the questionnaire was 
deemed to reflect implied consent. 
 
Participants completed an online questionnaire consisting of the measures described below. Control 
participants did not complete HF-related questions; all other aspects were identical. The question 
“Do you have heart failure?” was used to differentiate between groups. Participants provided their 
email address if they were willing to be contacted about future study follow-up. This information was 
stored securely and separately from the data. Data were anonymised to protect participant 
confidentiality. Dummy identifiers were assigned to allow linkage for follow-up. 
 
Measures 
Socio-demographic: Information was collected regarding age, gender, ethnicity, area of residence, 
marital status, and household composition (total number of adults and children under 18 years). 
 
Physical health: HF severity was measured using the self-assigned New York Heart Association 
(NYHA) classification scale (Holland et al., 2010). The 4-point NYHA scale is widely used to measure 
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functional status. Higher scores indicate greater symptom severity. Participants were also asked to 
list any other medical conditions. 
 
Fatigue was measured using the 9-item Fatigue Severity Scale (FSS) (Krupp et al., 1989). The FSS was 
designed to assess fatigue in chronic health conditions. Scores range from 9-63, with higher scores 
indicating greater fatigue severity. The FSS has shown good internal consistency (Cronbach’s α = .88-
.95) and test-retest reliability (r=.84) (Whitehead, 2009). 
 
COVID-19: Participants were asked whether they had been advised to shield during COVID-19. 
COVID-anxiety was measured using the 5-item Coronavirus Anxiety Scale (CAS) (Lee, 2020). Scores 
range from 0-20, with higher scores indicating greater anxiety. The CAS has shown good internal 
consistency (α = .80-.93) and appears to measure COVID-anxiety in a similar way regardless of age, 
gender, or race (Caycho-Rodríguez et al., 2021; Lee et al., 2020). A CAS score ≥9 was used to 
determine COVID-anxiety caseness (Lee, 2020). 
 
Psychological distress: Depressive symptoms were measured using the 9-item Patient Health 
Questionnaire (PHQ-9) (Spitzer et al., 1999). Scores range from 0-27 and higher scores indicate 
greater depression severity. Depression caseness was defined by a cut-off score ≥10 (Lichtman et al., 
2008; Meader et al., 2011).  
 
Anxiety symptoms were measured using the 7-item Generalised Anxiety Scale (GAD-7) (Spitzer et al., 
2006). GAD-7 scores range from 0-21, with higher scores indicating higher anxiety levels. Anxiety 
caseness was determined by a cut-off score ≥10 (Ivanovs et al., 2018; Spitzer et al., 2006). Both the 
PHQ-9 and GAD-7 are well-validated (Kroenke et al., 2001; Rutter & Brown, 2017), recommended in 
cardiac care for assessment of psychological wellbeing (Scottish Intercollegiate Guidelines Network, 
2017), and used routinely within heart failure services.  
 
Psychosocial: Coping style was measured using 6 items from the Brief-COPE questionnaire (Carver, 
1997). Consistent with previous HF research (Eisenberg et al., 2012), coping responses were grouped 
into two overarching categories: approach coping (active coping, positive reframing and acceptance 
subscales) and avoidant coping (denial, substance use and behavioural disengagement subscales). 
Higher scores indicate stronger likelihood to adopt the coping style. The Brief-COPE has been 
validated among participants responding to a range of adversities, including natural disasters and 




Perceived control was measured using the 7-item Personal Mastery Scale (PMS) (Pearlin & Schooler, 
1978) which assesses the extent to which one believes that they can control life events and 
circumstances. Scores range from 7-49, with higher scores indicating greater sense of mastery. The 
PMS is widely used in health research, including cardiac studies (Roepke & Grant, 2011), and has 
demonstrated acceptable internal consistency (α = .77-.79) (Kempen et al., 1999; Ranchor et al., 
2010). 
 
Loneliness was assessed using the 3-item UCLA Loneliness Scale (Hughes et al., 2004). Scores range 
from 3-9, with higher scores indicating greater feelings of loneliness. The scale has shown acceptable 
internal consistency (α = .72-.84), and convergent and discriminant validity among community-based 
populations (Hughes et al., 2004; Rico-Uribe et al., 2016). 
 
Social support was measured using the 7-item ENRICHD Social Support Inventory (ESSI) which 
comprises items on structural, instrumental and emotional support (Mitchell et al., 2003). Scores 
range from 8-34, with higher scores indicating greater social support. The scale has demonstrated 
good internal consistency (α = .86-.88), concurrent and predictive validity, and test-retest reliability 
within cardiac populations (Mitchell et al., 2003; Vaglio Jr et al., 2004).  
 
Sample size estimation 
A previous case control study by Lesman-Leegte et al. (2009) found 39% of elderly HF patients 
experienced clinically significant depressive symptoms compared to 21% of age- and gender-
matched community controls. Based on this study, G* Power (Faul et al., 2009) was used to calculate 
the sample size required to detect between-group differences in the proportion of cases and 
indicated a required sample of 90 per group (N = 180) (α = .05, β = .80). To the author’s knowledge, 
snowball sampling methods to recruit control participants have not previously been undertaken with 
HF populations. Participation rates and demographic characteristics of each group were reported to 
aid sample size estimations for future research. 
 
Adjusted analysis plan 
Given increased pressures on NHS services and reduction in routine clinics during the COVID-19 
pandemic, it was not possible to meet the recruitment target within the available timescale. Data 
analysis was therefore modified to use appropriate statistical methods for the sample size achieved.  
 
This paper adheres to the Strengthening the Reporting of Observational Studies in Epidemiology 
(STROBE) guidelines for reporting observational studies (von Elm et al., 2007). PHQ-9, GAD-7 and CAS 
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scores were dichotomised into caseness according to the clinical cut-offs described above. Following 
Teymoori et al. (2020) guidance, ordinary mean substitution was used for missing items on measures 
if less than one third of items were missing. Descriptive statistics were used to summarise feasibility 
data related to recruitment, missing data, acceptability of follow-up, and baseline characteristics.  
 
For categorical variables, between-group differences were tested using chi-square tests (or Fisher’s 
exact test, FET, if expected frequencies were <5). Given the sample size, exact methods were used to 
calculate significance levels. Continuous variables were tested using Welch’s t-tests as this is robust 
in the presence of unequal sample sizes and variances (Delacre et al., 2017). Relationships between 
key variables (e.g., gender, NYHA class, social support) and depression/anxiety scores among the HF 
group were tested using appropriate non-parametric tests. Confidence intervals and appropriate 
effect sizes were reported in line with published guidance (du Prel et al., 2009; Kotrlik et al., 2011; 





Recruitment was via third party clinicians and organisations passing the study advertisement to 
potential participants. Therefore, it was not possible to determine number of potential participants 
approached. Instead, a timeline of recruitment method and number recruited is reported in Figure 1. 
Four charities initially agreed to support study recruitment. One charity subsequently withdrew 
involvement due to delays in obtaining approvals. Eleven health boards agreed for the study to be 
shared with their HF clinicians through the HFHS and SHFNF. Three health boards did not agree: two 
withdrew due to staff shortages and the need to prioritise large-scale COVID-19 studies; one did not 
respond to requests for involvement (Appendix 2.3). All participants who decided to take part met 
the study criteria and completed the survey. The percentage of missing values across all variables 




Figure 1: Recruitment Graph 
 
For the snowball sampling method, it was anticipated that asking HF participants to pass on the study 
details to 2-3 close friends would provide roughly equal-sized and demographically matched samples. 
Forty-two HF participants (73.7%) and 15 control participants (26.3%) took part. Table 1 shows the 
demographic characteristics of the total sample and between groups. There were significant gender 
differences between groups (χ2(1, N = 57) = 6.17, p = .013, φ = .33), with equal numbers of males and 
females in the HF group but more females in the control group. No control participants were advised 
to shield, whereas 21.1% of HF participants were advised to shield and 5.3% were unsure (p = .036, 
FET, V = .36). There were no significant between-group differences for age (p = .964, FET, V = .17), 
ethnicity (p = .263, FET, φ = .22), marital status (p = .262, FET, V = .33), total number of people in the 
household (t(22.01) = .47, p = .642, 95% BCa CI [-.61, .97], d = .15), area of residence (p = .899, FET, V 




















Age  n (%)    .964 
18-24 1 (1.8) 1 (2.4) 0 (0.0)  
25-34 6 (10.5) 4 (9.5) 2 (13.3)  
35-44 5 (8.8) 3 (7.1) 2 (13.3)  
35-54 16 (28.1) 12 (28.6) 4 (26.7)  
55-64 15 (26.3) 11 (26.2) 4 (26.7)  
65-74 7 (12.3) 5 (11.9) 2 (13.3)  
75 and over 7 (12.3) 6 (14.3) 1 (6.7)  
Gender  n (%)    .013 
Male 23 (40.4) 21 (50.0) 2 (13.3)  
Female 34 (59.6) 21 (50.0) 13 (86.7)  
Ethnicity  n (%)    .263 
White 56 (98.2) 42 (100.0) 14 (93.3)  
Black, African, Caribbean or 
Black British 
1 (1.8) 0 (0.0) 1 (6.7)  
Marital status  n (%)    .262 
Single (never married) 12 (21.1) 7 (16.7) 5 (33.3)  
Married or civil partnership 22 (38.6) 18 (42.9) 4 (26.7)  
Relationship (living together) 12 (21.1) 10 (23.8) 2 (13.3)  
Relationship (not living together) 1 (1.8) 0 (0.0) 1 (6.7)  
Divorced or separated 8 (14.0) 6 (14.3) 2 (13.3)  
Widowed 2 (3.5) 1 (2.4) 1 (6.7)  
Total number in household  M [SD] 2.33 [1.19] 2.38 [1.15] 2.20 [1.32] .642 
Area of residence    .899 
Ayrshire & Arran 6 (10.5) 5 (11.9) 1 (6.7)  
Fife 4 (7.0) 3 (7.1) 1 (6.7)  
Grampian 2 (3.5) 1 (2.4) 1 (6.7)  
Greater Glasgow & Clyde 25 (43.9) 17 (40.5) 8 (53.3)  
Highland 3 (5.3) 3 (7.1) 0 (0.0)  
Lanarkshire 10 (17.5) 8 (19.0) 2 (13.3)  
Lothian 3 (5.3) 3 (7.1) 0 (0.0)  
Tayside 3 (5.3) 2 (4.8) 1 (6.7)  
Not reported 1 (1.8) 0 (0.0) 1 (6.7)  
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NYHA class  n (%)    - 
I - 6 (14.3) -  
II - 14 (33.3) -  
III - 19 (45.2) -  
IV - 3 (7.1) -  
Reported other physical/mental 
health conditions  n (%) 
28 (49.1) 22 (52.4) 6 (40.0) .410 
Advised to shield  n (%)    .036 
Yes 12 (21.1) 12 (28.6) 0 (0.0)  
No 42 (73.7) 27 (64.3) 15 (100.0)  
Unsure 3 (5.3) 3 (7.1) 0 (0.0)  
n = sample size, M = mean, SD = standard deviation 
 
 
Between-group comparisons of psychological distress and related variables 
Mean scores for depression, anxiety, and COVID-anxiety split by group are shown in Figure 2. Tests of 
between-group differences in symptoms of psychological distress found a medium effect size for 
COVID-anxiety (t(15.98) = -1.64, p = .122, 95% BCa CI [-4.04, .52], d = -.69), and small effect sizes for 
general anxiety (t(19.24) = -.87, p = .393, 95% BCa CI [-5.34, 2.19], d = -.29) and depression (t(19.34) = 






Figure 2: Mean scores and 95% confidence intervals for the psychological distress variables split by 
group. 
 
Mean scores for the other key variables split by group are shown in Figure 3. Tests of between-group 
differences for these variables found medium effect sizes for social support (t(22.80) = 2.03, p = .054, 
95% BCa CI [-.10, 10.22], d = .68), avoidant coping (t(18.77) = -1.68, p = .109, 95% BCa CI [-1.72, .19], 
d = -.61), and fatigue (t(26.84) = 1.93, p = .064, 95% BCa CI [-.54, 17.87], d = .56). A small effect size 
was found for loneliness (t(21.61) = -1.00, p = .328, 95% BCa CI [-2.15, .75], d = -.33) with negligible 
effect sizes found for perceived control (t(21.81) = .45, p = .661, 95% BCa CI [-6.02, 8.29], d = .15) and 





Figure 3: Mean scores and 95% confidence intervals for the other key variables split by group. 
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Prevalence of psychological distress between groups  
Prevalence rates for depression, anxiety and COVID-anxiety are reported in Table 2. Tests of 
between-group differences in prevalence found a medium effect size for COVID-anxiety caseness (p = 
.07, FET, φ = .32), small effect size for anxiety caseness (p = .14, FET, φ = .21), and negligible effect 
size for depression caseness (χ 2(1, N = 57) = .00, p = 1.00, φ = .00). 
 
Table 2. Prevalence of psychological distress overall and for each group. 
 Prevalence [95% BCa CI] 
Psychological distress 




Control group  
(15) 
Depression   33.9% [23.2, 44.6] 34.1% [20.5, 48.6] 33.3% [12.5, 55.6] 
Anxiety 19.6% [10.7, 28.6] 14.6% [5.3, 25.7] 33.3% [12.5, 55.6] 
COVID-anxiety 3.6% [.0, 8.9] 0% [-] 13.3% [.0, 33.3] 
CI = confidence interval 
 
HF group analysis  
Relationships between psychological distress and socio-demographic, health, and psychosocial 
variables were tested for the HF group (see Table 1 for frequencies of categorical variables and Table 
3 for relationships between continuous variables). 
 
Table 3.  Correlation matrix (rS) for study variables and depression/anxiety scores in the HF group. 
Variable 1 2 3 4 5 6 7 8 
1. Depression score -        
2. Anxiety score .73** -       
3. NYHA class .30 .09 -      
4. Fatigue .43** .25 .53** -     
5. Avoidant coping .31 .31 -.06 -.11 -    
6. Approach coping -.03 -.08 -.06 .22 .26 -   
7. Perceived control -.65** -.64** -.15 -.07 -.41** .28 -  
8. Loneliness .50** .35* .13 .19 .19 -.22 -.32* - 
9. Social support -.27 -.15 -.21 .15 -.36* .06 .26 -.67** 




For depression scores, a negative correlation with large effect size was found for perceived control (rS 
= -.65, p < .001, 95% BCa CI [-.81, -.39]). Positive correlations with moderate effect sizes were found 
for loneliness (rS = .50, p = .001, 95% BCa CI [.23, .73]) and fatigue (rS = .43, p = .005, 95% BCa CI [.16, 
.67]). A medium effect size was also found between presence of other health conditions and 
depression score (U = 127, z = -2.35, p = .019, r = .36), with depression scores higher among those 
reporting other health conditions than those who did not report other health conditions (median = 9 
and 5 respectively). Medium effect sizes were also found for relationships between depression score 
and gender (U = 296.5, z = 1.92, p = .055, r = .30), age (H(6) = 4.16, p = .655, ε2 = .10), shielding status 
(H(2) = 4.97, p = .083, ε2 = .12), NYHA class (rS = .30, p = .058, 95% BCa CI [.03, .56]) and avoidant 
coping (rS = .31, p = .050, 95% BCa CI [-.03, .60]), although these were not statistically significant. 
Small effect sizes were found for relationships between depression scores and marital status (H(4) = 
2.56, p = .634, ε2 = .06) and social support (rS = -.27, p = .095, 95% BCa CI [-.58, .08]), and a negligible 
association was found for approach coping (rS = -.03, p = .838, 95% BCa CI [-.40, .32]).  
 
For anxiety scores, a negative correlation with large effect size was found for perceived control (rS = -
.64, p < .001, 95% BCa CI [-.80, -.36]). A positive correlation with moderate effect size was found for 
loneliness (rS = .35, p = .025, 95% BCa CI [.02, .64]). A medium effect size was also found between 
presence of other health conditions and anxiety score (U = 113, z = -2.55, p = .011, r = .40), with 
anxiety scores higher among those reporting other health conditions than those who did not report 
other health conditions (median = 6 and 3 respectively). Medium effect sizes were also found for 
relationships between anxiety score and marital status (H(4) = 6.91, p = .141, ε2 = .17) and avoidant 
coping (rS = .31, p = .055, 95% BCa CI [-.04, .61]), although these were not statistically significant. 
Small effect sizes were found for relationships between anxiety scores and gender (U = 272, z = 1.63, 
p = .104, r = .25), age (H(6) = 2.36, p = .884, ε2 =  .06), shielding status (H(2) = 1.91, p = .384, ε2 = .05), 
fatigue (rS = .25, p = .125, 95% BCa CI [-.08, .57]) and social support (rS = -.15, p = .342, 95% BCa CI [-
.52, .21]). Negligible associations were found between anxiety scores and NYHA class (rS = .08, p = 
.590, 95% BCa CI [-.19, .36]) and approach coping (rS = -.08, p = .638, 95% BCa CI [-.43, .28]). 
 
Discussion 
Based on previous literature, Hypothesis 1 predicted that people with HF would have higher rates of 
psychological distress than controls during the COVID-19 pandemic. However, there were no 
significant differences in rates of psychological distress among the HF group compared to controls. 
Hypothesis 2 predicted that psychological distress would be associated with socio-demographic, 
health, and psychosocial variables in the HF group.  Greater levels of depression were found among 
people who reported lower levels of perceived control, higher levels of fatigue and loneliness, and 
54 
 
presence of other health conditions, with medium-large effect sizes. Moderate effect sizes for 
relationships between depressive symptoms and gender, age, shielding status, NYHA class and 
avoidant coping were not statistically significant. Greater levels of anxiety were found among people 
who reported lower levels of perceived control, higher levels of loneliness, and presence of other 
health conditions, with medium-large effect sizes. Moderate effect sizes for relationships between 
anxiety symptoms and marital status and avoidant coping were not statistically significant. 
 
Evaluation and implications  
Depression prevalence was higher across both groups (33.9% overall) than previously found in other 
COVID-19 studies. For example, UK population-based studies from the first COVID-19 lockdown 
found depression prevalence of 22.1% and 26.1% (O'Connor et al., 2020; Shevlin et al., 2020), 
consistent across a 6-week period (O'Connor et al., 2020). These studies also used the PHQ-9 with 
cut-off ≥10 for clinically significant symptoms so differences are not due to measures used. Shevlin et 
al. (2021) suggest mental health responses to COVID -19 are heterogenous and identified three 
distinct subgroups of individuals with different trajectories: stability, improvement and deterioration 
in mental health. Given the later timing of recruitment, it is possible the sample may have been over-
represented by the “deterioration” subgroup, with these individuals perhaps more likely to respond 
to a mental health study than individuals from the “stability” or “improvement” subgroupings.  
 
Anxiety prevalence among the HF group was 14.6%, lower than reported previously (e.g., 28.8% in a 
meta-analysis by Easton et al. (2016)). Rates of anxiety were higher in the control group (33.3%), 
although this was not statistically significant. Overall anxiety prevalence was 19.6% which is slightly 
lower than reported prevalence from early in the COVID-19 pandemic (Daly et al., 2020; O'Connor et 
al., 2020; Shevlin et al., 2020). Lower anxiety prevalence may be related to the timing of recruitment, 
although it is unclear why the HF group had lower rates of anxiety in comparison to previous pre-
COVID-19 studies. A medium effect size was found for COVID-anxiety in the opposite direction than 
expected, with 13.3% of controls and 0% of HF participants reporting clinically significant COVID-
anxiety. Thus, the perceived threat of COVID-19 and significant changes to healthcare do not seem to 
have led to increased anxiety among the HF group, with prevalence of both general and COVID-
anxiety lower than expected. 
 
Relationships between psychological distress and other related variables were consistent with 
previous research and with emerging evidence from the COVID-19 pandemic. The medium-large 
effect sizes found between depressive/anxiety symptoms and perceived control and avoidant coping 
are in keeping with Leventhal’s Common-Sense Model of illness which suggests such factors will 
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influence psychological adjustment to health threats, such as COVID-19. In addition, loneliness 
(Creese et al., 2021) and physical multimorbidity (Smith et al., 2020) have been associated with 
higher levels of poor mental health during the COVID-19 pandemic. These variables warrant further 
investigation as they may be useful in identifying individuals at-risk of psychological distress and 
potentially modifiable targets for intervention. 
 
Study strengths and limitations 
Our test of the feasibility of using snowball sampling with people with HF resulted in the control 
group being well-matched on most demographic variables, but sample size (HF group = 42; controls = 
15) and gender differed. Reasons for this are unclear as snowball sampling methods have previously 
been used effectively in health research including with hidden populations such as users of drugs 
(Lopes et al., 1996). The HF cohort was older than the general population and consequently may 
have been less likely to share the study online. Similarly, their immediate peers might have unable to 
access the online questionnaire. Reduced social interactions and shielding measures during COVID-19 
may have resulted in decreased opportunities to share the study. HF participants may also have been 
unwilling to share the study if they had not disclosed HF status to friends. Given the study was 
explicitly related to HF, some prospective control participants may have chosen not to participate. 
 
Whilst clinicians involved in recruitment were supportive of the study in principle, COVID-related 
pressures on services negatively impacted on recruitment. The small sample size (particularly for the 
control group) limits statistical power and results should be interpreted cautiously. Recruitment 
difficulties also highlight the importance of patient engagement in research and the potential value 
of including patient and public representatives when designing studies. Medium-large effect sizes 
were found for some non-significant results suggesting these analyses may have been underpowered 
and warrant further investigation. 
 
The self-selected nature of the sample may have led to participation bias. A previous representative 
UK study of newly diagnosed HF patients by Conrad et al. (2019) found mean age of 76.6, whereas 
most HF participants in this study were aged 35-64 (54.8%). This bias may be partially due to the 
survey being online as internet use has been found to be lower among older people and those with 
long-standing illness (Kearns & Whitley, 2019). Given COVID-19 circumstances, an online survey was 
the most feasible approach but limits generalisability of findings as results may not be representative 
of the wider HF population. Access to the internet has also been found to be poorer among 
individuals with mental health problems (Kearns & Whitley, 2019; Too et al., 2020) so individuals 




The self-report nature of HF status is a limitation, as Camplain et al. (2017) previously found low 
sensitivity of self-reported HF, and poor agreement between self-report and physician-diagnosed HF. 
HF diagnosis may not be explicitly discussed with patients, leading to lack of knowledge about their 
HF status (Camplain et al., 2017).  Therefore, some eligible individuals may not have taken part due 
to being unaware of a HF diagnosis. Conversely, some control participants could have had HF but 
been unaware of this.  Self-reported HF was the most feasible option as the survey was anonymous, 
but may be less reliable than other methods, such as accessing patient records. 
 
This study used widely accepted caseness cut-offs for PHQ-9 and GAD-7 allowing for comparison with 
other COVID-19 research looking at prevalence of psychological distress. However, there is evidence 
supporting alternative cut-offs for balancing sensitivity and specificity (e.g., eight for GAD-7 across a 
range of settings (Plummer et al., 2016) and six for PHQ-9 among cardiac outpatients (Thombs et al., 
2008)). Using lower cut-off scores would increase prevalence rates. Further research to validate the 
PHQ-9 and GAD-7 with HF patients and determine optimal cut-offs for diagnostic accuracy is 
warranted. Similarly, research using alternative methods such as structured clinical interviews may 
increase understanding of prevalence rates for depression and anxiety in this population.  
 
This study found low prevalence of COVID-anxiety (3.6%). The CAS is a new measure which has not 
yet been well-validated, and Lee et al. (2020) found sensitivity of cut-off score ≥9 was below the 
recommended criterion. A lower CAS cut-off score may be more appropriate for diagnostic accuracy 
in community-based populations. 
 
Due to the cross-sectional design, it is unknown whether prevalence of psychological distress among 
HF patients has changed during the COVID-19 pandemic or whether changes have followed the 
mental health trajectories identified by Shevlin et al. (2021). A longitudinal design was not feasible 
due to study constraints, but follow-up has been planned with a subsequent project. 
 
Conclusion 
This study extended previous research during the COVID-19 pandemic to a HF population. The study 
found higher depression prevalence (33.9%) and lower anxiety prevalence (19.6%) than previously 
reported by other HF and COVID-19 studies. There were no significant differences found in rates of 
psychological distress in the HF group compared to controls. Despite the relatively small sample size, 
medium-large effect sizes were found in the HF group for relationships between depressive and 
anxiety symptoms and related variables (such as perceived control, loneliness, and presence of other 
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health conditions). These factors warrant further investigation as they may be useful in identifying 
individuals at-risk of psychological distress and potentially modifiable targets for intervention. 
Planned follow-up should increase our understanding of mental health trajectories and adjustment 
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Appendix 1.1: British Journal of Health Psychology Author Guidelines 
AIMS AND SCOPE 
The British Journal of Health Psychology publishes original research on all aspects of psychology 
related to health, health-related behaviour and illness across the lifespan including: 
• experimental and clinical research on aetiology 
• management of acute and chronic illness 
• responses to ill-health 
• screening and medical procedures 
• psychosocial mediators of health-related behaviours 
• influence of emotion on health and health-related behaviours 
• psychosocial processes relevant to disease outcomes 
• psychological interventions in health and disease 
• emotional and behavioural responses to ill health, screening and medical procedures 
• psychological aspects of prevention  
 
MANUSCRIPT CATEGORIES AND REQUIREMENTS 
The types of paper invited are: 
• papers reporting original empirical investigations, using either quantitative or qualitative 
methods, including reports of interventions in clinical and non-clinical populations; 
• theoretical papers which report analyses on established theories in health psychology; 
• we particularly welcome review papers, which should aim to provide systematic overviews, 
evaluations and interpretations of research in a given field of health psychology (narrative 
reviews will only be considered for editorials or important theoretical discourses); and 
• methodological papers dealing with methodological issues of particular relevance to health 
psychology. 
Authors who are interested in submitting papers that do not fit into these categories are advised to 
contact the editors who would be very happy to discuss the potential submission. 
Papers describing quantitative research (including reviews with quantitative analyses) should be no 
more than 5000 words (excluding the abstract, reference list, tables and figures). Papers describing 
qualitative research (including reviews with qualitative analyses) should be no more than 6000 words 
(including quotes, whether in the text or in tables, but excluding the abstract, tables, figures and 
references). In exceptional cases the Editor retains discretion to publish papers beyond this length 
where the clear and concise expression of the scientific content requires greater length (e.g., 
explanation of a new theory or a substantially new method). Authors must contact the Editor prior to 
submission in such a case. 
All systematic reviews must be pre-registered. The pre-registered details should be given in the 
methods section but blinded for peer review (i.e., ‘the review was preregistered at [BLINDED]’); the 
details can be added at proof stage. Registration documents should be uploaded as title page files 
when possible, so that they are available to the Editor but not to reviewers. 
Please refer to the separate guidelines for Registered Reports. 
COVID-19 Research 
The BJHP has received an overwhelming number of COVID-19 related submissions. We can only 
consider papers that are providing new and novel data on COVID-19.  We particularly welcome 
submissions of intervention studies. Furthermore, rapid peer review for COVID-19 submissions has 
now ended. COVID-19 papers will now be handled alongside other standard submissions. 
 
PREPARING THE SUBMISSION 
Free Format Submission 
British Journal of Health Psychology now offers free format submission for a simplified and 
streamlined submission process. 
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Before you submit, you will need: 
• Your manuscript: this can be a single file including text, figures, and tables, or separate files – 
whichever you prefer. All required sections should be contained in your manuscript, 
including abstract, introduction, methods, results, and conclusions. Figures and tables should 
have legends. References may be submitted in any style or format, as long as it is consistent 
throughout the manuscript. If the manuscript, figures or tables are difficult for you to read, 
they will also be difficult for the editors and reviewers. If your manuscript is difficult to read, 
the editorial office may send it back to you for revision. 
• The title page of the manuscript, including a data availability statement and your co-author 
details with affiliations. (Why is this important? We need to keep all co-authors informed of 
the outcome of the peer review process.) You may like to use this template for your title 
page. 
Important: the journal operates a double-blind peer review policy. Please anonymise your 
manuscript and prepare a separate title page containing author details. (Why is this important? We 
need to uphold rigorous ethical standards for the research we consider for publication.) 
• An ORCID ID, freely available at https://orcid.org. (Why is this important? Your article, if 
accepted and published, will be attached to your ORCID profile. Institutions and funders are 
increasingly requiring authors to have ORCID IDs.) 
 To submit, login at https://www.editorialmanager.com/bjhp/default.aspx and create a new 
submission. Follow the submission steps as required and submit the manuscript. 
If you are invited to revise your manuscript after peer review, the journal will also request the 
revised manuscript to be formatted according to journal requirements as described below. 
Revised Manuscript Submission 
Contributions must be typed in double spacing. All sheets must be numbered. 
Cover letters are not mandatory; however, they may be supplied at the author’s discretion. They 
should be pasted into the ‘Comments’ box in Editorial Manager. 
Parts of the Manuscript 
The manuscript should be submitted in separate files: title page; statement of contribution; main 
text file; figures/tables; supporting information. 
Title Page 
You may like to use this template for your title page. The title page should contain: 
• A short informative title containing the major key words. The title should not contain 
abbreviations (see Wiley's best practice SEO tips); 
• A short running title of less than 40 characters; 
• The full names of the authors; 
• The author's institutional affiliations where the work was conducted, with a footnote for the 
author’s present address if different from where the work was conducted; 
• Abstract; 
• Keywords; 




Please refer to the journal’s Authorship policy in the Editorial Policies and Ethical Considerations 
section for details on author listing eligibility. When entering the author names into Editorial 
Manager, the corresponding author will be asked to provide a CRediT contributor role to classify the 
role that each author played in creating the manuscript. Please see the Project CRediT website for a 
list of roles. 
Abstract 
For articles containing original scientific research, a structured abstract of up to 250 words should be 
included with the headings: Objectives, Design, Methods, Results, Conclusions. Review articles 
should use these headings: Purpose, Methods, Results, Conclusions. As the abstract is often the most 
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widely visible part of your paper, it is important that it conveys succinctly all the most important 
features of your study. You can save words by writing short, direct sentences. Helpful hints about 
writing the conclusions to abstracts can be found here. 
Keywords 
Please provide appropriate keywords. 
Acknowledgments 
Contributions from anyone who does not meet the criteria for authorship should be listed, with 
permission from the contributor, in an Acknowledgments section. Financial and material support 
should also be mentioned. Thanks to anonymous reviewers are not appropriate. 
Statement of Contribution 
All authors are required to provide a clear summary of ‘what is already known on this subject?’ and 
‘what does this study add?’. Authors should identify existing research knowledge relating to the 
specific research question and give a summary of the new knowledge added by your study. Under 
each of these headings, please provide 2-3 (maximum) clear outcome statements (not process 
statements of what the paper does); the statements for 'what does this study add?' should be 
presented as bullet points of no more than 100 characters each. The Statement of Contribution 
should be a separate file. 
Main Text File 
As papers are double-blind peer reviewed, the main text file should not include any information that 
might identify the authors. 
The main text file should be presented in the following order: 
• Title 
• Main text 
• References 
• Tables and figures (each complete with title and footnotes) 
• Appendices (if relevant) 
Supporting information should be supplied as separate files. Tables and figures can be included at 
the end of the main document or attached as separate files but they must be mentioned in the text. 
• As papers are double-blind peer reviewed, the main text file should not include any 
information that might identify the authors. Please do not mention the authors’ names or 
affiliations and always refer to any previous work in the third person. 
• The journal uses British spelling; however, authors may submit using either option, as 
spelling of accepted papers is converted during the production process. 
References 
References in published papers are formatted according to the Publication Manual of the American 
Psychological Association (6th edition). However, references may be submitted in any style or 
format, as long as it is consistent throughout the manuscript.  
Tables 
Tables should be self-contained and complement, not duplicate, information contained in the text. 
They should be supplied as editable files, not pasted as images. Legends should be concise but 
comprehensive – the table, legend, and footnotes must be understandable without reference to the 
text. All abbreviations must be defined in footnotes. Footnote symbols: †, ‡, §, ¶, should be used (in 
that order) and *, **, *** should be reserved for P-values. Statistical measures such as SD or SEM 
should be identified in the headings. 
Figures 
Although authors are encouraged to send the highest-quality figures possible, for peer-review 
purposes, a wide variety of formats, sizes, and resolutions are accepted. 
Click here for the basic figure requirements for figures submitted with manuscripts for initial peer 
review, as well as the more detailed post-acceptance figure requirements. 
Legends should be concise but comprehensive – the figure and its legend must be understandable 
without reference to the text. Include definitions of any symbols used and define/explain all 
abbreviations and units of measurement. 
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Colour figures. Figures submitted in colour may be reproduced in colour online free of charge. Please 
note, however, that it is preferable that line figures (e.g. graphs and charts) are supplied in black and 
white so that they are legible if printed by a reader in black and white. If an author would prefer to 
have figures printed in colour in hard copies of the journal, a fee will be charged by the Publisher. 
Supporting Information 
Supporting information is information that is not essential to the article, but provides greater depth 
and background. It is hosted online and appears without editing or typesetting. It may include tables, 
figures, videos, datasets, etc. 
Click here for Wiley’s FAQs on supporting information. 
Note: if data, scripts, or other artefacts used to generate the analyses presented in the paper are 
available via a publicly available data repository, authors should include a reference to the location of 
the material within their paper. 
General Style Points 
For guidelines on editorial style, please consult the APA Publication Manual published by the 
American Psychological Association. The following points provide general advice on formatting and 
style. 
• Language: Authors must avoid the use of sexist or any other discriminatory language. 
• Abbreviations: In general, terms should not be abbreviated unless they are used repeatedly 
and the abbreviation is helpful to the reader. Initially, use the word in full, followed by the 
abbreviation in parentheses. Thereafter use the abbreviation only. 
• Units of measurement: Measurements should be given in SI or SI-derived units. Visit 
the Bureau International des Poids et Measures (BIPM) website for more information about 
SI units. 
• Effect size: In normal circumstances, effect size should be incorporated. 
• Numbers: numbers under 10 are spelt out, except for: measurements with a unit (8mmol/l); 





























Appendix 1.2: Search strategy 
Searches conducted 22.01.2021 
Ovid host MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily 
and Versions(R) 1946 to December 17, 2020 N=2182 
1. Depression/  
2. exp Depressive Disorder/  
3. depress*.tw.  
4. 1 or 2 or 3  
5. Heart Failure/  
6. ((heart or cardiac) adj failure).tw.  
7. 5 or 6  
8. Epidemiologic Studies/  
9. exp Cohort Studies/  
10. (cohort adj stud*).tw.  
11. cohort analy*.tw.  
12. (follow up or follow-up).tw.  
13. (observational adj stud*).tw.  
14. longitudinal.tw.  
15. predict*.tw. 
16. 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 
17. 4 and 7 and 16 
18. limit 17 to English language 
 
Ovid host EMBASE 1947-Present, updated daily N=4449 
1. Depression/  
2. exp Depressive Disorder/  
3. depress*.tw.  
4. 1 or 2 or 3  
5. Heart Failure/  
6. ((heart or cardiac) adj failure).tw.  
7. 5 or 6  
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8. Epidemiologic Studies/  
9. exp Cohort Studies/  
10. (cohort adj stud*).tw.  
11. cohort analy*.tw.  
12. (follow up or follow-up).tw.  
13. (observational adj stud*).tw.  
14. longitudinal.tw.  
15. predict*.tw. 
16. 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 
17. 4 and 7 and 16 
18. limit 17 to English language 
 
EBSCO host CINAHL N=974 
S17 S3 AND S6 AND S15 Limiter: English Language 
S16 S3 AND S6 AND S15  
S15 S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14  
S14 T1 predict* OR AB predict* 
S13 TI longitudinal OR AB longitudinal  
S12 TI (observational N1 stud*) OR AB (observational N1 stud*)  
S11 TI (follow up or follow-up) OR AB (follow up or follow-up)  
S10 TI cohort analy* OR AB cohort analy*  
S9 TI (cohort N1 stud*) OR AB (cohort N1 stud*)  
S8 (MH "Prospective Studies+")  
S7 (MH "Epidemiological Research+")  
S6 S4 OR S5 
S5 TI ((heart or cardiac) N1 failure) OR AB ((heart or cardiac) N1 
failure)  
S4 (MH "Heart Failure+")  
S3 S1 OR S2  
S2 TI depress* OR AB depress*  






EBSCO host APA PSYCINFO N=930 
S16 S3 AND S6 AND S14 Limiter: English Language 
S15 S3 AND S6 AND S14  
S14 S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13  
S13 T1 predict* OR AB predict* 
S12 TI longitudinal OR AB longitudinal  
S11 TI observational N1 stud* OR AB observational N1 stud*  
S10 TI (follow up or follow-up) OR AB (follow up or follow-up)  
S9 TI cohort analy* OR AB cohort analy*  
S8 TI cohort N1 stud* OR AB cohort N1 stud*  
S7 DE "Cohort Analysis" OR DE "Followup Studies" OR DE 
"Longitudinal Studies" OR DE "Prospective Studies" OR DE 
"Repeated Measures"  
S6 S4 OR S5 
S5 TI ((heart or cardiac) N1 failure) OR AB ((heart or cardiac) N1 
failure)  
S4 DE "Heart Disorders" OR DE "Angina Pectoris" OR DE 
"Arrhythmias (Heart)" OR DE "Coronary Thromboses" OR DE 
"Myocardial Infarctions"  
S3 S1 OR S2  
S2 TI depress* OR AB depress*  
S1 DE "Major Depression" OR DE "Anaclitic Depression" OR DE 
"Dysthymic Disorder" OR DE "Endogenous Depression" OR DE 
"Late Life Depression" OR DE "Postpartum Depression" OR DE 
"Reactive Depression" OR DE "Recurrent Depression" OR DE 
"Treatment Resistant Depression"  
 
Cochrane Library N=513 
#1 MeSH descriptor: [Depression] explode all trees 
#2 MeSH descriptor: [Depressive Disorder] explode all trees 
#3 (depress*):ti,ab,kw (Word variations have been searched) 
#4 #1 or #2 or #3 
#5 MeSH descriptor: [Heart Failure] explode all trees 
#6 ((heart or cardiac) near/1 failure):ti,ab,kw (Word variations have been searched) 
#7 #5 or #6 
#8 MeSH descriptor: [Epidemiologic Studies] explode all trees 
#9 MeSH descriptor: [Cohort Studies] explode all trees 
#10 (cohort near/1 stud*):ti,ab,kw (Word variations have been searched) 
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#11 (cohort analy*):ti,ab,kw 
#12 (follow up or follow-up).ti,ab,kw 
#13 (observational adj stud*):ti,ab,kw 
#14 (longitudinal):ti,ab,kw 
#15 #8 or #9 or #10 or #11 or #12 or #13 or #14 































Appendix 1.3: NHLBI risk of bias assessment tool 
Criteria Yes No 
Other (CD, 
NR, NA)* 
1. Was the research question or objective in this paper clearly 
stated? 
   
2. Was the study population clearly specified and defined?    
3. Was the participation rate of eligible persons at least 50%?    
4. Were all the subjects selected or recruited from the same or 
similar populations (including the same time period)? Were 
inclusion and exclusion criteria for being in the study prespecified 
and applied uniformly to all participants? 
   
5. Was a sample size justification, power description, or variance 
and effect estimates provided? 
   
6. For the analyses in this paper, were the exposure(s) of interest 
measured prior to the outcome(s) being measured? 
   
7. Was the timeframe sufficient so that one could reasonably expect 
to see an association between exposure and outcome if it existed? 
   
8. For exposures that can vary in amount or level, did the study 
examine different levels of the exposure as related to the outcome 
(e.g., categories of exposure, or exposure measured as continuous 
variable)? 
   
9. Were the exposure measures (independent variables) clearly 
defined, valid, reliable, and implemented consistently across all 
study participants? 
   
10. Was the exposure(s) assessed more than once over time?    
11. Were the outcome measures (dependent variables) clearly 
defined, valid, reliable, and implemented consistently across all 
study participants? 
   
12. Were the outcome assessors blinded to the exposure status of 
participants? 
   
13. Was loss to follow-up after baseline 20% or less?    
14. Were key potential confounding variables measured and 
adjusted statistically for their impact on the relationship between 
exposure(s) and outcome(s)? 
   
 *CD, cannot determine; NA, not applicable; NR, not reported 
 
Quality Rating (Good, Fair, or Poor)  
Additional Comments (If POOR, 






Appendix 1.4: Final quality assessment ratings agreed by primary and secondary rater 
Study  
Criteria Total 
score 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Alosco et 
al. (2014) 




Y Y Y Y N Y Y Y Y N Y NA Y Y 11/13 
Carney et 
al. (2020) 












Y Y NR Y N Y Y Y Y Y Y NA NR N 9/13 
Park & Lee 
(2020) 
Y N NR Y N Y Y Y Y Y Y NA NR Y 9/13 
Park et al. 
(2006) 
Y N Y Y N Y Y Y Y Y Y NA Y Y 11/13 
Park et al. 
(2011) 
Y N NR Y N Y Y Y Y Y Y NA Y Y 10/13 
Park et al. 
(2014) 
Y N NR Y N Y Y Y Y Y Y NA Y Y 10/13 
Shimizu et 
al. (2014) 
Y Y Y Y N Y Y Y Y Y Y NA N Y 11/13 
Turvey et 
al. (2006) 
Y N N Y N Y Y Y Y N Y N NR Y 8/14 
Wirtz et al. 
(2010) 
Y N NR Y Y Y Y Y Y N Y NA NR Y 9/13 
Key: Y = Yes; N = No; NA = Not applicable; NR = Not reported; highlighted items indicate initial 












Appendix 1.5: Quality assessment full results and record of discrepancy resolution 
Study  
Criteria 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Alosco et 
al. (2014) 




Y Y Y Y N Y Y Y Y N/Y Y NA Y Y 
Carney et 
al. (2020) 
















Y N/Y NR Y N Y Y Y Y CD/Y Y NA NR Y 
Park et al. 
(2006) 
Y N/Y Y Y Y/N Y Y Y Y Y Y NA Y Y 
Park et al. 
(2011) 
Y N/Y NR Y N Y Y/N Y Y Y Y NA Y Y 
Park et al. 
(2014) 




Y Y NR/Y Y N Y Y Y Y Y Y NA N/Y Y 
Turvey et 
al. (2006) 
Y N/Y N Y N Y Y Y Y N/Y Y N Y/NR Y 
Wirtz et 
al. (2010) 
Y N/Y NR Y Y Y Y Y Y N/Y Y NA NR Y 
Key: Y = Yes; N = No; CD = Cannot determine; NA = Not applicable; NR = Not reported; highlighted 
items indicate discrepancies between raters (primary rating/secondary rating) 
 
Question Discussion and agreed outcome 
2) Was the study population 
clearly specified and defined? 
Discussed that all discrepancies lay with whether study time period had 
been reported. Raters agreed that ‘time period’ was necessary in defining 
the study population. All studies which did not report ‘time period’ were 
kept as a ‘no’ rating. 
3) Was the participation rate 
of eligible persons at least 
50%? 
Alosco et al. (2014) – Secondary rater agreed that the study did not report 
how many participants were initial approached. Rating kept as ‘not 
reported’.  
Havranek et al. (2004), Lossnitzer et al (2013) & Shimizu et al. (2014) – 
Primary rater agreed that data was reported on number of eligible 
participants and participation rate was over 50%. Ratings changed to ‘yes’. 
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5) Was a sample size 
justification, power 
description, or variance and 
effect estimates provided? 
Park et al. (2006) – Raters agreed that power had been discussed in the 
study but that power calculations were not reported. Agreed to change 
this item to a ‘no' rating. 
7) Was the timeframe 
sufficient so that one could 
reasonably expect to see an 
association between exposure 
and outcome if it existed? 
Park et al. (2011) & Park et al. (2014) – Follow-up period was shorter than 
for other included studies (3 months). Raters decided that 3-month follow-
up was a sufficient time frame for depression to develop. Ratings kept as 
‘yes’. 
10) Was the exposure(s) 
assessed more than once over 
time? 
Brouwers et al. (2014), Turvey et al. (2006) & Wirtz et al. (2010) – Raters 
agreed that exposure(s) were only assessed at baseline, so rating was kept 
as a ‘no’. 
Park & Lee (2020) – Method was not entirely clear but raters concluded 
that it was likely the survey packet was distributed at both time points. 
Rating was changed to a ‘yes’. 
13) Was loss to follow-up 
after baseline 20% or less? 
Havranek et al. (2004) – Raters agreed 34% of participants were lost to 
follow-up, rating kept as a ‘no’ 
Shimizu et al. (2014) – Raters agreed 26% of participants were lost to 
follow-up, rating kept as a ‘no’ 
Turvey et al. (2006) – Primary rater agreed that it was unclear whether any 
participants dropped out as study only reported numbers with complete 
data. Rating was changed to ‘not reported’. 
14) Were key potential 
confounding variables 
measured and adjusted 
statistically for their impact 
on the relationship between 
exposure(s) and outcome(s)? 
Lossnitzer et al. (2020) – Discussion regarding key potential confounding 
variables. Raters concluded that baseline depression score was a key 
potential confounding variable and that this had not been controlled for, 





































































































Appendix 2.6: Major research project proposal 
 
Title: Mental health and predictors of psychological distress among people with heart failure during 




Psychological distress is common among people with heart failure (HF). The coronavirus (COVID-19) 
pandemic is likely to significantly impact on mental health and wellbeing. People with HF have 
increased vulnerability to COVID-19 and may be at increased risk of psychological distress. Several 
related factors, such as fatigue and social support, may be predictors of psychological adjustment 
among people with HF during the COVID-19 pandemic. 
 
Aims 
The primary aim of this study is to describe and examine rates of psychological distress and 
adjustment among people with HF compared to controls during the COVID-19 pandemic. The study 
will also investigate which variables predict psychological distress among both groups. An exploratory 
sub-study will track changes in psychological distress more frequently, enabling investigation of daily 
fluctuations in distress and exploration of potential causal relations among related variables.  
 
Methods 
The study will use a case-control, cross-sectional design. Participants with HF and controls will 
complete an online questionnaire consisting of several measures (socio-demographic, physical health, 
COVID-19 related, psychological distress and psychosocial). An exploratory sub-study will follow a 




The study will increase understanding of the mental health impact of a pandemic situation among a 
vulnerable group, namely people with HF. Identifying predictors of psychological distress may help to 










Since January 2020, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which causes 
coronavirus disease 2019 (COVID-19) has spread rapidly across the world. In the UK, the first case of 
COVID-19 was diagnosed in January 2020 and community transmission has since led to a rapid 
increase in cases (see McBride et al. (2020) for timeline). This has resulted in extraordinary changes to 
life and working practices in the UK. Schools, restaurants, and non-essential shops have been closed, 
and people have been told to stay at home and avoid non-essential travel and contact with others 
(Public Health England, 2020a).  
 
Whilst research is still emerging, people with heart failure (HF) could be particularly vulnerable to 
COVID-19 as they may have reduced cardiovascular functional reserve and the COVID-19 infection 
may precipitate a myocardial infarction or increase metabolic demand (Tan and Aboulhosn, 2020). 
They have therefore been advised to be particularly careful in trying to minimise the risk of 
contracting COVID-19 (Pumping Marvellous, 2020; Scottish Government, 2020). In addition, 
particularly high-risk individuals with HF have been advised to ‘shield’ by staying at home at all times 
and avoiding all face-to-face contact for at least twelve weeks (Public Health England, 2020b). 
Reduced social contact and worries about practical issues such as finances, obtaining food supplies 
and accessing medical care are likely to have an additional impact on mental health. Consequently, 
Holmes et al. (2020) argue research investigating the mental health impact of the COVID-19 
pandemic and how this can be mitigated should be an immediate priority, including the impact for 
vulnerable groups, such as people with HF. 
 
Prior to the COVID-19 pandemic, psychological distress had previously been found to be common 
among patients with HF (Holly and Sharp, 2012). In line with previous research, this study will define 
psychological distress as a ‘state of emotional suffering characterized by symptoms of depression and 
anxiety (Drapeau et al., 2012). Previous research looking at prevalence rates for depression and 
anxiety disorders among people with HF have found them to be higher than in the general population 
(Celano et al., 2018). Previous meta-analyses estimate around 21.5% of patients with HF have 
clinically significant symptoms of depression (Rutledge et al., 2006) and 28.8% have clinically 
significant levels of anxiety (Easton et al., 2016). Psychological distress among patients with HF is 
associated with adverse health outcomes including increased mortality, morbidity and use of 
healthcare resources (Celano et al., 2018; Holly and Sharp, 2012). Vulnerable groups, such as people 
with HF, may also be at increased risk of psychological distress during the COVID-19 pandemic due 
to factors such as increased health- and finance-related anxieties, social isolation and disrupted access 
to health and social care services (Brooks et al., 2020; Holmes et al., 2020; Scottish Government, 
2020). Thus, people with HF may represent an at-risk group for psychological distress during the 




Evidence from previous outbreaks of infectious respiratory diseases suggests psychological distress 
may persist, or even worsen, over time (Brooks et al., 2020; Gardner and Moallef, 2015; McBride et 
al., 2020). As lockdown restrictions begin to lift, some individuals may experience a more chronic 
stress response with persistent difficulties with symptoms of low mood and/or anxiety. Previous 
research looking at psychological outcomes following traumatic events, including disease outbreaks, 
suggests psychological adjustment is influenced by a number of factors – such as age, gender, 
education, income change, physical health, level of trauma exposure, fear of the disease, social support 
and coping style (Bonanno et al., 2007; Polizzi et al., 2020; Xu et al., 2011). Initial reports from 
research into COVID-19 among the general population suggest that symptoms of depression and 
anxiety spiked after lockdown restrictions were introduced, and that higher rates of anxiety and 
depression were associated with a number of factors, including presence of an underlying health 
condition (COVID-19 Psychological Research Consortium (C19PRC), 2020). The network approach 
to mental health posits that psychopathology arises from, and is maintained by, networks of causally 
connected and interacting symptoms (Borsboom, 2017; Fried and Cramer, 2017). Fried et al. (2020) 
used dynamic network models to investigate mental health during the initial stages of the COVID-19 
pandemic and identified negative reinforcing cycles of loneliness, mental health problems and 
COVID-19 related worries. 
 
Holmes et al. (2020) suggest that COVID-19 related research should investigate underlying 
mechanisms and possible predictors of psychological distress and adjustment. This may help to inform 
both our understanding of maintenance and/or remission of psychological distress and the 
development of interventions to improve mental wellbeing (Holmes et al., 2020). For people with HF, 
research suggests specific factors are associated with increased risk of psychological distress and 
reduced likelihood of psychological adjustment over time. Leventhal’s Common-Sense Model (CSM) 
of illness posits that when a threat is perceived, individuals develop cognitive and emotional 
representations of this which directly influence coping responses and subsequent outcomes (Leventhal 
et al., 2003). Based on this model, factors such as severity of illness, perceived control and coping 
style influence psychological adjustment to health threats, such as the current COVID-19 pandemic.  
 
Psychological distress has previously been associated with sociodemographic characteristics (such as 
age, sex, and employment status) (Holly and Sharp, 2012; Scherer et al., 2007), number of physical 
and emotional problems (Holly and Sharp, 2012; Scherer et al., 2007), greater severity of HF (Scherer 
et al., 2007), fatigue (Yu et al., 2004), avoidant coping and pessimism (Trivedi et al., 2009). 
Conversely, living with a partner and high levels of social support appear to be protective for patients 
with HF, and increase the likelihood and speed with which psychological distress reduces over time 
(Koenig, 1998; Scherer et al., 2007; Trivedi et al., 2009; Yu et al., 2004). Thus, previous findings in 
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relation to psychological adjustment to disease outbreaks and among people with HF suggest that a 
number of sociodemographic, health and psychosocial factors may be significant predictors of 
psychological distress for people with HF during the COVID-19 pandemic. 
 
Aims 
The primary aim of this study is to describe and examine rates of psychological distress and 
adjustment among people with HF compared to controls during the COVID-19 pandemic. The study 
will also investigate which variables predict psychological distress among both groups. An exploratory 
sub-study will track changes in psychological distress more frequently, enabling investigation of daily 
fluctuations in distress and exploration of potential causal relations among related variables.  
 
Hypotheses 
1. Assuming COVID-19 restrictions are prolonged for vulnerable individuals, psychological 
distress will be higher among people with HF compared to controls.  
2. Psychological distress will be associated with a number of variables among people with HF 
and controls, such as socio-demographic (age, gender, marital status, household composition), 
COVID-19 (anxiety, shielding), health (presence of HF, HF severity, total number of physical 
and emotional problems, fatigue) and psychosocial factors (coping style, perceived control, 
social support, loneliness).  
 
Plan of Investigation 
Participants and recruitment procedure 
Participants diagnosed with HF will be recruited through links with the Heart Failure Hub Scotland 
and national advocacy groups, such as Cardiomyopathy UK, Pumping Marvellous and Chest Heart 
Stroke Scotland. Individuals with HF will be invited to take part in the study through advertising 
within these services via social media networks and email databases where individuals have given 
permission to be contacted about relevant research. Through the HF Hub Scotland, HF clinicians will 
be informed of the study and invited to support recruitment. This may involve HF nurses being invited 
to pass on study information to patients. A snowball sampling method (Goodman, 1961) will be used 
to recruit control participants. Snowball sampling has previously been used effectively in health 
research for case-control designs (LOPES et al., 1996; Rezaei et al., 2011) and has the advantage of 
increasing the likelihood of recruiting demographically matched samples. Participants with HF will be 
asked to pass on details of the comparison survey to 2-3 close friends who do not live within the same 
household; these individuals will be used as controls. Potential participants will be provided with an 
information sheet and complete a set of short screening questions to ensure they meet the 




Inclusion and exclusion criteria 
Participants will be aged 18 or over, able to understand English and resident of the UK. Participants 
must have the technology and ability to complete the questionnaire online. Participants who wish to 
take part in the exploratory sub-study will need to have access to a smartphone using Android or iOS 




Socio-demographic: Information will be collected regarding age, gender, ethnicity, area of residence, 
marital status, and household composition (number of adults and children under 18 years).  
 
Physical health: Participants will be asked to report any medical conditions. HF severity will be 
measured using the self-assigned New York Heart Association classification scale (SA-NYHA) 
(Holland et al., 2010). The 4-point NYHA scale is used worldwide in clinical and research practice to 
measure functional status, with higher scores indicating greater symptom severity and limitations to 
functioning.  
 
Fatigue will be measured using the 9-item Fatigue Severity Scale (FSS) (Krupp et al., 1989). The FSS 
was designed to assess fatigue in chronic health conditions. Higher scores indicate more severe 
fatigue. The FSS has demonstrated good psychometric properties for research into a variety of chronic 
health conditions (Whitehead, 2009). 
 
COVID-19: The 5-item Coronavirus Anxiety Scale (CAS) will be used to assess COVID-related 
anxiety. Higher scores indicate greater anxiety, with CAS scores ≥9 indicative of dysfunctional levels 
of anxiety (Lee, 2020). Participants will also be asked whether they have been advised to shield at 
home during COVID-19.  
 
Psychological distress: The 9-item Patient Health Questionnaire (PHQ-9) (Spitzer et al., 1999) will be 
used to measure symptoms of depression. Scores range from 0-27 and higher scores indicate greater 
severity of depression. Symptoms of anxiety will be measured using the 7-item Generalised Anxiety 
Scale (GAD-7) (Spitzer et al., 2006). GAD-7 scores range from 0-21 with higher scores indicating 
higher levels of anxiety. Both the PHQ-9 and GAD-7 are well-validated (Kroenke et al., 2001; Rutter 
and Brown, 2017), recommended in cardiac care for assessment of psychological wellbeing (Scottish 
Intercollegiate Guidelines Network (SIGN), 2017) and used routinely within heart failure services.  
 
Psychosocial: Coping style will be measured using 6 items from the Brief-COPE questionnaire 
(Carver, 1997). Consistent with previous research among patients with HF (Eisenberg et al., 2012), 
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coping responses will be grouped into two overarching categories – approach coping (active coping, 
positive reframing, and acceptance subscales) and avoidant coping (denial, substance use and 
behavioural disengagement subscales). Higher scores indicate a stronger likelihood to adopt the 
coping style. The Brief COPE has been validated among participants responding to a wide range of 
adversities, including natural disasters and physical conditions (Carver, 1997; Eisenberg et al., 2012).  
 
Perceived control will be measured using the 7-iten Personal Mastery Scale (PMS) (Pearlin and 
Schooler, 1978) which assesses the extent to which one believes that one can control life events and 
circumstances. Higher overall scores indicate a greater sense of mastery. The PMS has strong 
structural validity (Pearlin and Schooler, 1978) and has previously been used in cardiac-related 
research (Roepke and Grant, 2011). 
 
Social support will be measured using the 7-item ENRICHD Social Support Inventory (ESSI). The 
ESSI was developed by identifying items predictive of mortality in cardiovascular patients and 
comprises items on structural, instrumental, and emotional support (Mitchell et al., 2003). Individual 
items are summed with higher scores indicating greater social support. The scale has demonstrated 
concurrent and predictive validity and test-retest reliability within cardiac populations (Mitchell et al., 
2003; Vaglio Jr et al., 2004).  
 
Loneliness will be assessed using the 3-item UCLA Loneliness Scale (Hughes et al., 2004). Scores 
range from 3-9 with higher scores indicating greater feelings of loneliness. The scale has shown 
satisfactory internal consistency, and convergent and discriminant validity among community-based 
populations (Hughes et al., 2004; Rico-Uribe et al., 2016). 
 
Ecological Momentary Assessment (EMA) 
The EMA will include 10 items to assess psychological wellbeing, health-related stress, and COVID-
19 stress. Participants will be asked how often, over the last three hours, they have experienced 
specific symptoms of depression and anxiety using a modified version of the PHQ-4 (Kroenke et al., 
2009). Six items adapted from Fried et al. (2020) related to tiredness, loneliness, social interaction, 




The study will take a case-control, cross-sectional design to investigate rates of psychological distress 
and related variables among people with HF and controls during the COVID-19 pandemic. An 
exploratory sub-study will follow a small number of participants with HF in greater depth four times 
per day for a week, allowing changes in psychological wellbeing and COVID-19 or health-related 
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stress to be tracked through EMA (Shiffman et al., 2008). There may also be potential for longitudinal 
follow-up in future. 
 
Research procedures 
Participants will be asked to complete an online questionnaire consisting of the measures described 
above. The questionnaire will take an estimated 10-15 minutes to complete. Control participants will 
not be asked to complete HF-related questions; all other aspects of the questionnaire will be identical. 
Participants will be asked to provide an email address if they would be willing to be contacted about 
future study follow-up. 
 
Participants with HF will be asked if they would also be willing to take part in an exploratory EMA 
sub-study. Previous EMA research suggests that studies assessing highly variable constructs, such as 
mood, should be measured multiple times per day (Kirtley et al., 2019) and that completion rates tend 
to decline over time (Ono et al., 2019; Rintala et al., 2020). In line with Fried et al. (2020), participants 
will therefore be asked to complete the EMA survey of psychological wellbeing and health/COVID-19 
related stressors four times daily. To reduce participant burden, participants will be asked to complete 
these surveys for one week only and surveys will take under two minutes to complete. Participants 
will receive a push notification prompt asking them to complete the EMA survey at set times of the 




Descriptive statistics will be used to summarise participant characteristics and study variables. 
Psychological distress will be defined by caseness (i.e., whether clinically significant symptoms of 
anxiety and/or depression are present). For hypothesis 1, in line with Lesman-Leegte et al. (2009), 
between-group differences in dichotomised depressive and anxious symptoms will be analysed using 
chi-square test. For hypothesis 2, in line with Scherer et al. (2007), logistic regression analyses will be 
used to identify predictors of psychological distress among both people with HF and controls. 
Stepwise backward elimination will be used to remove variables with p>0.05 as the level for removing 
effects.  
 
For the exploratory sub-study, slopes of the EMA variables will be investigated to explore whether 
items changed over time. Following Fried et al. (2020), two-step multilevel vector auto-regression will 
be used to estimate dynamic network models with all variables at a given timepoint regressed on 
variables of the previous assessment. The network models will be visualised in graphs containing 





Justification of sample size  
A previous case control study by Lesman-Leegte et al. (2009) found that 39% of elderly patients with 
HF experienced clinically significant depressive symptoms compared to 21% of age- and gender-
matched community controls. In addition, research suggests that rates of psychological distress have 
increased during the COVID-19 pandemic in the general population with 27.75% of participants 
reporting clinically significant symptoms of depression and/or anxiety (Shevlin et al., 2020). Based on 
Lesman-Leegte et al.’s (2009) study, G* Power (Faul et al., 2009) was used to estimate sample size for 
between-group effects and indicated a required sample of 90 per group (N = 180) (α = 0.05, β = 0.80). 
 
Guidelines from Bujang et al. (2018) on logistic regression in clinical research suggest that a rule of 
thumb of 10 events per variable (EPV) is appropriate for logistic regression using stepwise analysis. 
They propose a sample size formula of n = 100 + xi (where x is EPV and i represents number of 
independent variables). With 14 possible predictors, this study would therefore need a minimum of 
240 participants. Previous research looking at predictors of psychological distress among patients with 
HF, Scherer et al. (2007) investigated 16 variables longitudinally and found that four factors (baseline 
distress, emotional problems, social support and NYHA classification) independently predicted 
distress at follow-up. Using this paper, G* Power (Faul et al., 2009) was used to estimate sample size 
for logistic regression with multiple covariates (α = 0.05, β = 0.95, assumed event rate at baseline = 
0.3). This indicated a required sample size of between 89 and 263 based on odds ratios between 0.54 
and 5.51 (as found in Scherer et al. (2007)). Using the more conservative estimate, this study will 
therefore aim to recruit 263 participants. 
 
As far as the researchers are aware, EMA studies among people with HF have not previously been 
undertaken. Given the exploratory nature of this sub-study, all participants with HF will be invited to 
take part. Participation and compliance rates for EMA will be described to aid sample size estimations 
for future research.  
 
Settings and Equipment 
Data collection will occur through an online questionnaire hosted through the JISC Online Surveys 
tool which is compatible for both computer and smartphone devices. EMA data will be collected by 
participants downloading the SEMA3 smartphone app. Equipment required will be an encrypted 
computer to store data and access to SPSS and R software for data analysis. 
 
Health and safety issues 
Participants will be asked questions related to their current mood and a range of other psychological 
variables. There is a risk that this may be difficult and cause distress for some individuals. Potential 
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participants will be fully informed of this in the participant information sheet before they agree to 
participate. They will be told that questions which relate to their mood are for research purposes only 
and are not diagnostic. Participants will be informed that if they feel distressed during the study and 
wish to withdraw their participation, they may do so at any point. In addition, participants will be 
advised that they may wish to contact their GP, Breathing Space or the Samaritans if feel they require 
further assistance. No practical risks are anticipated as data collection will take place online.  
 
Ethical issues 
Participation in the study will be voluntary and there will be no cost, reimbursement, or compensation 
for taking part. Potential participants will be given the opportunity to contact the researcher if they 
have questions about taking part in the study. Participants will also be told they are free to withdraw 
from the study at any time and can leave questions blank if desired. Participants will complete the 
questionnaire online so will not provide written consent to participate. Instead, potential participants 
will be asked to complete an online consent page to confirm they consent to take part in the study.  
 
Participants will be asked to provide an email address if they would be willing to take part in the EMA 
sub-study or future study follow-up. This information will be stored securely and separately from the 
data collected and no other personal identifiable data will be collected. Once collected, data will be 
anonymised to protect participant confidentiality. Dummy identifiers will be assigned to allow linkage 
with follow-up data. Data will be processed and stored in accordance with the General Data Protection 
Regulation (2018) and NHS GG&C policies. Participants will be informed of this before taking part.  
 
The study will recruit participants through links with the Heart Failure Hub Scotland and national 
advocacy groups. Since the project will constitute an NHS research project, ethical approval will be 
sought from the NHS ethics committee.  
 
Timetable 
Final proposal – May 2020 
Final approved proposal and ethics application – June 2020 
Data collection – Summer 2020  
Data analysis and write-up – Autumn 2020 – Spring 2021 
Final MRP submission – July 2021 
Viva – September 2021 
 
Practical Applications 
The study will increase understanding of the mental health impact of a pandemic situation, specifically 
COVID-19, among a vulnerable group, namely people with HF. It will help to clarify whether this 
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population represents an at-risk group in need of additional targeted mental health support. Reducing 
psychological distress is particularly pertinent among people with HF given the previously established 
link between distress and poor health outcomes. Identifying predictors of psychological distress may 
help to inform clinical assessment in terms of key factors related to risk of distress. The study may be 
useful in informing the development of interventions to improve mental wellbeing. For instance, 
interventions which focus on increasing social support or help people with HF to manage fatigue may 
reduce psychological distress and improve adjustment. Future longitudinal follow-up may also 
increase our understanding of maintenance and/or remission of psychological distress among people 
with HF during disease outbreaks.  
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